 
 
CLINICAL STUDY PROTOCOL  
 
 
NCT0512148 [ADDRESS_690303] OF EDP1815 IN 
PARTICIPANTS FOR THE TREATMENT OF  MILD, 
MODERATE AND SEVERE  ATOPIC DERMATITIS  
 
PROTOCOL EDP1815 -207 
Version 5.0 / [ADDRESS_690304] Number: 2021 -001805 -63 
IND Number: [ZIP_CODE]  
Sponsor  
EVELO Biosciences, Inc.  
Cambridge, MA, [ZIP_CODE]  
[LOCATION_003]  
Protocol/Amendment number  Date  Type of 
amendment  
Protocol 5.[ADDRESS_690305] OF ABBREVIATIONS  ................................ ................................ ................................ .... 9 
PROTOCOL SUMMARY  ................................ ................................ ................................ ....... 11 
1. INTRODUCTION  ................................ ................................ ................................ ...........  13 
1.1. Atopic Dermatitis  ................................ ................................ ................................ .............  13 
1.2. Previous Experience with EDP1815 and Rationale for Treating Atopic Dermatitis  ....... 14 
2. STUDY OBJECTIVE(S)  ................................ ................................ ................................ . 17 
2.1. Primary Objectives  ................................ ................................ ................................ ...........  17 
2.2. Secondary Objectives  ................................ ................................ ................................ ....... 17 
2.3. Exploratory Objectives  ................................ ................................ ................................ .... 18 
3. STUDY VARIABLES  ................................ ................................ ................................ ..... 19 
3.1. Efficacy Variable(s)  ................................ ................................ ................................ .........  19 
3.1.1.  Primary Efficacy Variable(s)  ................................ ................................ ...............  19 
3.1.2.  Secondary Efficacy Variable(s)  ................................ ................................ ...........  19 
3.2. Pharmacokinetic and Pharmacodynamic Variable(s)  ................................ ......................  20 
3.3. Safety Variables  ................................ ................................ ................................ ...............  20 
3.4. Exploratory Variables  ................................ ................................ ................................ ...... 20 
4. STUDY DESIGN  ................................ ................................ ................................ .............  22 
4.1. Study Description  ................................ ................................ ................................ .............  22 
4.2. Study Duration per Participant  ................................ ................................ .........................  22 
4.3. Planned Number of Participants  ................................ ................................ ......................  23 
4.4. Anticipated Regions and Countries  ................................ ................................ .................  23 
4.5. Schedule of Study Assessments  ................................ ................................ .......................  24 
4.6. Schematic Study Diagram  ................................ ................................ ................................  28 
4.7. Rationale for study design and selection of dose  ................................ .............................  29 
4.7.1.  Placebo Rationale  ................................ ................................ ................................  29 
4.7.2.  Dose Rationale  ................................ ................................ ................................ ..... 29 
5. SELECTION AND WITHDRAWAL OF PARTICIPANTS  ................................ ..........  31 
5.1. Inclusion criteria  ................................ ................................ ................................ ..............  31 
5.2. Exclusion criteria  ................................ ................................ ................................ .............  32 
5.3. Screen Failures  ................................ ................................ ................................ .................  34 
5.3.3.  Rescreening  ................................ ................................ ................................ ..........  34 
5.4. Discontinu ation from Treatment and/or Withdrawal  ................................ .......................  [ADDRESS_690306] to Follow -Up ................................ ................................ ................................  36 
6. STUDY TREATMENT(S)  ................................ ................................ ..............................  [ADDRESS_690307](s)  ................................ ................................ ...............  [ADDRESS_690308](s) to be Administered  ................................ ...............  37 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 6 of 114 
8.2. Validated Investigator’s Global Assessment  ................................ ................................ ... 53 
8.3. SCORing Atopic Dermatitis  ................................ ................................ ............................  53 
8.4. Patient Oriented Eczema Measure  ................................ ................................ ...................  54 
8.5. Dermatology Life Quality Index  ................................ ................................ ......................  54 
8.6. Peak Pruritus Numerical Rating Scale (PP -NRS)  ................................ ............................  54 
8.7. Sleep Disturbance Numerical Rating Scale (SD -NRS)  ................................ ...................  [ADDRESS_690309]  ................................ ................................ ...... 56 
9.2. Adverse Drug Reactions  ................................ ................................ ................................ .. 56 
9.3. Serious Adverse Events  ................................ ................................ ................................ ... 56 
9.4. Reporting and Recording AEs  ................................ ................................ .........................  57 
9.4.1.  Assessment of AEs  ................................ ................................ ..............................  58 
9.4.2.  Assessment of Severity  ................................ ................................ ........................  58 
9.4.3.  Assessment of Causality  ................................ ................................ ......................  59 
9.4.4.  Description of Adverse Events  ................................ ................................ ............  59 
[IP_ADDRESS].  Rule for Repetition of an AE  ................................ ................................ ..... 59 
9.5. Reporting Serious Adverse Events  ................................ ................................ ..................  60 
9.5.5.  Follow Up of Adverse Events  ................................ ................................ ..............  60 
9.6. Pregnancy  ................................ ................................ ................................ .........................  60 
9.7. Overdose  ................................ ................................ ................................ ..........................  61 
9.8. Safety Signal Detection  ................................ ................................ ................................ .... 61 
9.9. Study Halting Criteria  ................................ ................................ ................................ ...... 61 
9.10.  Laboratory Measurements  ................................ ................................ .....................  62 
9.10.1.  Review of Laboratory Measurements  ................................ ................................ .. 63 
9.10.2.  Blood Volumes  ................................ ................................ ................................ .... 63 
9.11.  Biomarkers  ................................ ................................ ................................ .............  63 
9.11.1.  Genetic Testing  ................................ ................................ ................................ .... 63 
9.11.2.  Immune Protein Markers  ................................ ................................ .....................  64 
9.11.3.  Transcription Analysis  ................................ ................................ .........................  64 
9.11.4.  Microbiome Sample  ................................ ................................ .............................  64 
9.12.  Other Safety Measurements  ................................ ................................ ...................  64 
9.12.1.  Vital Signs, Height and Weight  ................................ ................................ ...........  64 
9.12.2.  Physical Exam ination  ................................ ................................ ..........................  64 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 7 of 114 
9.12.3.  12-Lead Electrocardiogram  ................................ ................................ .................  65 
9.13.  Non-Safety Measurements  ................................ ................................ .....................  65 
9.13.1.  Digital Photography  ................................ ................................ .............................  65 
10. STUDY MANAGEMENT AND ADMINISTRATION  ................................ .................  66 
10.1.  Adherence to protocol  ................................ ................................ ............................  66 
10.2.  Monitoring  ................................ ................................ ................................ .............  66 
10.2.1.  Definition of Source Data  ................................ ................................ ....................  66 
10.2.2.  Source Data Verification  ................................ ................................ .....................  67 
10.3.  Data Management  ................................ ................................ ................................ .. 67 
10.3.1.  Data Quality Assurance  ................................ ................................ .......................  67 
10.3.2.  Case Report Form Completion  ................................ ................................ ............  68 
10.3.3.  Data Entry and Reconciliation  ................................ ................................ .............  68 
10.3.4.  Participant Screening & Enrollment Log/Participant Identification Code List  ... 68 
10.4.  Termination of the Study  ................................ ................................ .......................  69 
10.5.  Archiving and Data Retention  ................................ ................................ ...............  69 
10.6.  Audit and Inspection  ................................ ................................ ..............................  69 
10.7.  Good Clinical Practice  ................................ ................................ ...........................  70 
11. STATISTICS  ................................ ................................ ................................ ...................  71 
11.1.  Definition of Analysis Sets  ................................ ................................ ....................  71 
11.1.1.  Participant Analysis Sets  ................................ ................................ .....................  71 
11.1.2.  Defined Data Point Sets  ................................ ................................ .......................  71 
11.2.  General Statistical Considerations  ................................ ................................ .........  72 
11.3.  Estimands and Intercurrent Events  ................................ ................................ ........  74 
11.3.1.  Primary Estimand and Supplementary Estimands of the Primary Objective  ...... 74 
11.3.2.  Secondary Estimands  ................................ ................................ ...........................  76 
11.3.3.  Exploratory Efficacy Estimands  ................................ ................................ ..........  77 
11.3.4.  Safety Estimands  ................................ ................................ ................................ . 79 
11.4.  Planned Analyses  ................................ ................................ ................................ ... 79 
11.4.1.  Analysis of Primary Estimand  ................................ ................................ .............  79 
11.4.2.  Analysis of Supplementary Estimands on the Primary Objective  .......................  80 
11.4.3.  Cohort 4 Sensitivity Analysis of the Primary Estimand  ................................ ...... 80 
11.4.4.  Analysis of Secondary Estimands  ................................ ................................ ....... 80 
11.4.5.  Analysis of Exploratory Estimands  ................................ ................................ ..... 81 
11.4.6.  Analysis of Safety Estimands  ................................ ................................ ..............  82 
11.4.7.  Other Analyses  ................................ ................................ ................................ ..... 82 
11.5.  Handling of Protocol Deviations  ................................ ................................ ...........  82 
11.6.  Handling of Dropouts or Missing Data  ................................ ................................ .. 82 
11.7.  Planned Interim Analysis and Data Monitoring  ................................ ....................  82 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 8 of 114 
11.8.  Determination of Sample Size  ................................ ................................ ...............  83 
12. ETHICS AND REGULATORY REQUIREMENTS  ................................ ......................  85 
12.1.  Informed Consent ................................ ................................ ................................ ... 85 
12.2.  Participant Identification Cards  ................................ ................................ .............  85 
12.3.  Institutional Review Boards and Independent Ethics Committees  ........................  85 
12.4.  Participant Privacy  ................................ ................................ ................................ . 86 
12.5.  Protocol Amendments  ................................ ................................ ............................  87 
12.6.  Insurance  ................................ ................................ ................................ ................  87 
12.7.  Financial Disclosures  ................................ ................................ .............................  87 
12.8.  Publications  ................................ ................................ ................................ ............  87 
12.8.1.  Dissemination of Clinical Study Data  ................................ ................................ . 87 
13. REFERENCES  ................................ ................................ ................................ ................  88 
14. APPENDICES  ................................ ................................ ................................ .................  91 
14.1.  Hanifin and Rajka (1980) Criteria for Diagnosis of Atopic Dermatitis  .................  [ADDRESS_690310] OF TABLES  
Table 4 -1:Schedule of Assessments ................................ ................................ .........................  24 
Table 6 -1: IMP to be Administered  ................................ ................................ .........................  38 
Table 11 -1: Intercurrent Event Strategies for the Primary and Supplementary 
Estim ands ................................ ................................ ................................ .........  75 
Table 11 -2: Secondary Estimand Details  ................................ ................................ .................  77 
Table 11 -3: Exploratory Estimand Details  ................................ ................................ ..............  78 
Table 11 -4: Safety Endpoint Details  ................................ ................................ ........................  79 
Table 14 -1: Highly Effective Contraceptive Methods  ................................ ........................  [ADDRESS_690311] OF FIGURES  
Figure 4 -1: Schematic Diagram  ................................ ................................ ...............................  [ADDRESS_690312] Research Organization  
DLQI  Dermatology Life Quality Index  
DNA  Deoxyribonucleic Acid  
DPS Data Point Set  
EC1 or EC2  Enteric Coating  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
EMA/EMEA  European Medicines Agency  
EASI  Eczema Area and Severity Index  
EudraCT  European Union Drug Regulating Authorities Clinical Trials  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HADS  Hospi[INVESTIGATOR_531732]1815 -[ADDRESS_690313]  Upper Limit of Normal  
vIGA or IGA  Validated Investigator Global Assessment  
WGS  Whole Genome Sequencing  
WOCBP  Woman of Child -Bearing Potential  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 11 of 114 
PROTOCOL SUMMARY  
 
Study Objectives:  The primary objective is to show superiority of EDP1815 over placebo in the 
treatment of atopic dermatitis.  The secondary objectives are to further evaluate the efficacy, safety 
and tolerability of EDP1815.  Exploratory objectives aim to evaluate the bes t daily dose and 
frequency of dosing for EDP1815 in the treatment of atopic dermatitis, the time to onset of clinical 
response to EDP1815 and the effect of EDP1815 treatment on blood biomarkers.  
 
Primary endpoint: The Eczema Area and Severity Index (EASI) will be utilized to measure the 
extent and severity of a participant’s atopic dermatitis.  The percentage of participants achieving 
EASI -50 (percentage of participants with a ≥ 50% reduction in EASI score from base line) at Week 
16 will be utilized to evaluate the efficacy of EDP1815 over placebo. Participants requiring use of 
topi[INVESTIGATOR_531733] 28 days before the Week 16 visit or who withdraw 
from the study prior to the Week 16 visit for  reasons considered related to study treatment will be 
considered as non -responders.  
 
Secondary endpoints:  The EASI Score will also be utilized to measure other aspects of clinical 
benefit of EDP1815 in the treatment of atopic dermatitis.  In addition to  EASI, the Validated 
Investigator’s Global Assessment (vIGA), the body surface area (BSA) of skin affected by [CONTACT_531772], the SCORing Atopic Dermatitis (SCORAD), the use of Rescue Medications, the 
Dermatology Life Quality Index (DLQI), the Peak Prur itus Numerical Rating Scale (PP -NRS), the 
Sleep Disturbance Numerical Rating Scale (SD -NRS) and the Patient Oriented Eczema Measure 
(POEM) will be measured throughout the study.  
 
The severity and frequency of Adverse Events will be used to evaluate the sa fety and tolerability 
of EDP1815.  
 
Exploratory endpoints: A number of exploratory endpoints will be evaluated to determine further 
aspects of treatment efficacy including time to achieve clinical response and patient reported health 
outcomes.  Changes in e osinophils, immune protein markers and immune cell RNA profile will be 
used to evaluate the effect of EDP1815 treatment on biomarkers in blood. A fecal sample will be 
used for microbiome profiling. Human Leukocyte Antigen (HLA) typi[INVESTIGATOR_531734].  
 
Brief Study Design: This study will evaluate EDP1815 in participants with mild, moderate, and 
severe atopic dermatitis, to compare efficacy, safety, and tolerability to plac ebo. The 
Investigational Medicinal Product (IMP) is EDP1815 or matching placebo. The study will be 
blinded to the participants, Investigator, and Sponsor.   
 
Approximately 405 participants will be randomized to receive either EDP1815 or placebo (295 to 
EDP 1815: 110 to placebo) and treated for [ADDRESS_690314] to participate in an 
Open Label Extension (OLE) Protocol for EDP1815, if available.   Cohor ts 1, 2 & 3 will be run 
concurrently , and Cohort 4 recruitment will commence  after enrollment for Cohorts 1, 2, & 3 are 
completed.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 12 of 114 
Participants will be dosed with EDP1815  or matching placebo administered as the following:  
 
• Cohort 1:  1.6x1011 total cells of EDP1815 or matching placebo administered as 2 capsules 
once daily. 
 
• Cohort 2:  6.4x1011 total cells of EDP1815 or matching placebo administered as 2 capsules 
once daily. 
 
• Cohort 3:  6.4x1011 total cells of EDP1815 or matching placebo administered as 1 capsule 
of 3.2x1011 cells twice daily.  
 
• Cohort 4:  8.0x1010 total cells of EDP1815 or matching placebo administered as 1 capsule 
once daily. 
 
Participants in Cohorts 1, 2, & 3 will be randomized in a 3:1 ratio (225 to EDP1815: 75 to placebo). 
Participants in Cohort 4 will be randomized in a 2:1 ratio (70 to EDP181 5: 35 to placebo).  
Randomization to Cohort 4 will not start before randomization to Cohorts 1, 2 & [ADDRESS_690315] before  the end of recruitment  to Cohorts 1, 2 & 3 to 
check the assumptions used for the sample size calculation  and to ensure that there is no imbalance  
between treatment groups caused by [CONTACT_531773] .  
 
The data collected for Cohorts 1, 2 & 3 may also be locked and analyzed prior to t he completion 
of Cohort 4.  
 
Study Duration: The maximum study duration is up to [ADDRESS_690316] to 
participate in the Open Label Extension (OLE protocol), their study duration during this study 
would be a maximum of 20 weeks.  
 
 
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 13 of 114 
1. INTRODUCTION  
 
1.1. Atopic Dermatitis  
Atopic dermatitis (AD), also kno wn as (atopic) eczema, is a chronic, highly symptomatic relapsing 
inflammatory skin disease, affecting up to 30% of children and 10% of adults (Bieber, Atopic 
Dermatitis, 2010) .  While AD often begins in infancy or childhood, i t may become chronic and 
persist into adulthood (Katoh, 2019) . Depending on factors such as severity of skin lesions or body 
surface area coverage, the disease can be classified clinically as mild, moderate, or severe.  
 
Patients with AD typi[INVESTIGATOR_531735], exudates, papulovesicles, scales and crusts, often symmetrically distributed on the body 
(Katoh, 2019) .  The disease typic ally follows a variable course with acute flares, often triggered 
by [CONTACT_84042], which cause a worsening of skin disease and symptoms. More chronic lesions 
are associated with thickened lichenified skin which may be accompanied by [CONTACT_21173][INVESTIGATOR_531736] (Bieber, Atopic Dermatitis, 2010) . The primary symptom at both stages 
of disease is typi[INVESTIGATOR_531737] (itch). Such signs and symptoms are associated with a substantial 
patient burden that typi[INVESTIGATOR_531738], mood disturbance and mental health 
problems (Simpson, 2012) , poor quality of life, and social functioning (Kiebert, 2002) . 
 
AD, like other atopic disease, is characterized by a T helper type 2 (Th2) cell -mediated 
inflammation, with up -regulation of Th2 cytokines including IL -4, IL -5, and IL -13 (Indra, 2013) . 
In turn, this leads to increased IgE prod uction by B -cells, which can trigger release of cytokines 
and chemical mediators such as histamine from mast cells and Langerhans cells. In addition, 
thymic stromal lymphoprotein is thought to be a critical cytokine in the triggering and maintenance 
of AD  (Indra, 2013) , and is associated with migration of Th2 cells into the skin lesion  (Katoh, 
2019) . The resulting systemic inflammation drives the disease pathology and patient symptoms, 
with the resu ltant scratching of pruritic lesions further worsening the skin lesions and the skin 
barrier function, further driving the disease process. Therefore, targeting systemic inflammation 
improves disease signs and symptoms – for example systemic corticosteroid s typi[INVESTIGATOR_531739], but generally are not acceptable as a long -term treatment due to 
associated side -effects (Lee, 2016) . 
 
In general, treatment of AD is aimed at a combination of resolution of skin  disease and 
improvement of symptoms such as itch (acute therapy), and also prevention of further flares 
(maintenance therapy). Emollients, also known as moisturizers, are the first -line and baseline 
therapy for all severities of disease, and act by [CONTACT_531774] (Lee, 2016) . There are a number of other topi[INVESTIGATOR_531740] (TCS) and topi[INVESTIGATOR_22726] (TCI)  (Katoh, 2019) . Unfortunately, there 
are associated problems with such treatments including adverse effects, limitations in efficacy, and 
low patient acceptability and tolerability, particularly when used as chronic treatment options.  
 
In the US, th ere are currently no licensed oral treatments for atopic dermatitis; while in the 
European Union, only ciclosporin is licensed as an oral treatment. Due to its associated risks and 
side-effects, such as renal failure, ciclosporin is generally only recommen ded for short -term use 
(Katoh, 2019) . Other anti -inflammatory treatments, such as methotrexate or azathioprine, are 
therefore used off license in order to reduce the Th2 -driven systemic inflammation. These systemic 

EDP1815 -[ADDRESS_690317] associated risks and side -effects and are therefore not suitable for a large 
population of patients, including many of those with mild and moderate disease. Finally, for 
patients with moderate -to-severe disease, Dupi[INVESTIGATOR_12460] (dupi[INVESTIGATOR_12458]) is now license d as a biologic 
injectable treatment and is currently used to treat a small proportion of patients with such disease 
severity.  
 
A 2016 patient survey (National Eczema Association, 2016)  highlights and summarizes what it is 
like for patient living with atopic dermatitis:  
• 84% are “very” or “extremely” bothered by [CONTACT_298454], 83% by [CONTACT_531775], and 63% by [CONTACT_932]/redness  
• 75% stated AD interferes with their job and house chores, 71% say it interferes with 
hobbies, and 65% don’t feel as healthy  because of AD  
• Nearly half of people with moderate to severe AD report their disease “interferes with their 
social life, intimate relations, and relationships with their spouse and children”  
• 1 in 3 takes one or more hours per day to treat their AD  
• More tha n half are dissatisfied overall with each of the following treatments that they are 
using or have used: topi[INVESTIGATOR_8826], topi[INVESTIGATOR_22726], phototherapy, and oral 
medications  
 
The conclusion from this study was that there is a “lack of safe a nd effective treatments” for AD, 
allowing for “unchecked symptoms [which] contribute to the range of health issues”. This sums 
up the unmet need for and importance of further oral treatments for AD.  
 
1.2. Previous Experience with EDP1815 and Rationale for Treat ing Atopic 
Dermatitis  
Evelo Biosciences, Inc. (Evelo) is developi[INVESTIGATOR_531741] a 
new understanding of how immunity and inflammation are controlled. Evelo’s medicines are 
selected for their ability to modulate the small intestinal axis (SINTAX ™). This is the network of 
anatomical and functional connections that has evolved to link the small intestine and the rest of 
the body. It links small intestinal mucosal immunology with systemic inflammation and is 
accessible with or al SINTAX medicines.  
 
The inflammatory control mechanisms of SINTAX down -regulate multiple inflammatory 
pathways including those which have been validated with targeted antibody therapi[INVESTIGATOR_014], but without 
the side effects seen with antibody therapeutics or bro adly acting oral kinase inhibitors. This occurs 
via specific interactions between the oral SINTAX therapy and small intestine enterocytes and 
immune cells. These interactions drive the development of an immune -regulatory subset of 
lymphocytes that travel from the gut to the systemic circulation, via the mesenteric lymph nodes. 
Here, these circulating cells mediate their effects on peripheral inflammation at the target sites 
(e.g., atopic dermatitis skin).  
 
EDP1815 is a pharmaceutical preparation of a single strain of Prevotella histicola , originally 
isolated from a duodenal biopsy. The drug substance is essentially non -viable and non -replicating, 
with a cell viability of <0.02%. It has not been genetically modified. It does not colonize the gut 
nor a lter the microbiome and has no detectable systemic exposure following oral dosing to date – 
i.e., it is gut -restricted.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 15 of 114 
Prevotella  as a genus are gram -negative, obligate anaerobic bacteria that are natural human 
commensals found in the oral cavity and gas trointestinal (GI) tract. Strains of Prevotella  have been 
found in all human populations tested to date, at abundances ranging from <1% to nearly 50% of 
total fecal microbial load (Vandeputte, Kathagen, & D'hoe, 2017) . 
 
In vitro studies of EDP1815 in human and mouse cellular assays and in vivo models support its 
use in the treatment of immunoinflammatory diseases, including atopic dermatitis. Oral 
administration of EDP1815 to mice led to striking therapeutic effects on de layed -type 
hypersensitivity (DTH), imiquimod -induced skin inflammation, fluorescein isothiocyanate (FITC) 
cutaneous hypersensitivity, collagen -induced arthritis (CIA) (Marietta, Murray, & Luckey, 2016)  
and experimental acute ence phalomyelitis (EAE) (Mangalam, Shahi, & Luckey, 017)  in-vivo 
models. EDP1815 was shown to down -regulate key Th2 -related cytokines including IL -4 and IL -
31. No potentially related adverse effects were seen in the animals used in t hese experiments with 
daily dosing for up to 3 weeks, or alternate day dosing for over 7 weeks. Ex vivo 
immunophenotypi[INVESTIGATOR_531742] T cell numbers and regulatory 
dendritic cells (DCs) in spleen and mesenteric lymph nodes, a s well as decreases in pro -
inflammatory cytokines such as IL-[ADDRESS_690318] been exposed 
to EDP1815 or placebo.  A total of 458 participants received EDP1815: 54 healthy volunteers, 234 
patients with mild to moderate psoriasis, 48 patients with mild to moderate AD and 122 patients 
with COVID -19 infection. A total of 165 subjects r eceived placebo: 16 healthy volunteers, 117 
patients with mild to moderate psoriasis, 24 patients with mild to moderate AD and 8 patients with 
COVID 19 infection.  To date, EDP1815 is well tolerated with a safety profile comparable to 
placebo – there are n o AEs of special interest and no related serious adverse events have been seen.  
 
In the phase 1b study EDP1815 -101, 16 participants in cohort 7 were treated with EDP1815 
capsules at a dose of 8.0 x 1011 cells once daily for 8 weeks, with a further 8 partic ipants given 
matching placebo. Clinically meaningful and significant responses were observed at the end of the 
treatment period, in terms of the changes in EASI, vIGA*BSA and SCORAD, as well as within 
the patient -reported outcomes, which also found improve ments in itch and sleep scores.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 16 of 114 
The available evidence to date has found EDP1815 to be very well tolerated with evidence for 
proof of concept as an effective treatment for atopic dermatitis. A well tolerated oral therapy could 
offer significant benefit i n atopic dermatitis for all severities of disease.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 17 of 114 
2. STUDY OBJECTIVE(S)  
 
2.1. Primary Objectives  
The study will compare four treatment regimens of EDP1815 with placebo in participants with 
atopic dermatitis who are using twice daily topi[INVESTIGATOR_39669].  
 
The primary comparison of interest is the odds ratio for achievement of an EASI -[ADDRESS_690319] to use of topi[INVESTIGATOR_531743] 28 days prior to the Week 16 assessment being considered 
as non -responders. A composite strategy will a lso be used for participants who withdraw from the 
study prior to the Week 16 visit for reasons relating to study medication (e.g., related adverse 
event, lack of efficacy, requirement of for alternative therapy) also being considered as non -
responders. A ‘while on treatment’ strategy will be used for participants who withdraw from the 
study prior to Week 16 for reasons considered unrelated to study medication, with the achievement 
of response at Week 16 being considered missing.  
 
A number of supportive an alyses to check the robustness of the primary estimand approach will 
be performed. These will consider  
• Topi[INVESTIGATOR_531744] [ADDRESS_690320] and using the composite strategy only for  use less than 14 
days prior to the Week 16 visit  
• Using a ‘while on treatment’ strategy for rescue medications with any Week 16 data 
collected less than 28 days after rescue medication use being considered missing.  
• Using a ‘while on treatment’ strategy for discontinuation of the study for any reason before 
Week 16.  
• Using a principal stratum strategy excluding participants who are non -compliant with 
respect to study medication or emollient use (<75% compliance), use a prohibited 
background therap y, take at least one dose of the incorrect study medication or who are 
unblinded prior to the end of the study.  
• Using an alternative composite strategy for topi[INVESTIGATOR_531745], with all 
participants who use any topi[INVESTIGATOR_531746] 1 and 
Week 16 considered as non -responders at the Week 16 visit.  
 
2.2. Secondary Objectives  
The secondary objectives of this study are the following:  
 
1. To evaluate the clinical benefit of EDP1815 in the treatment of atopic dermatitis . 
 
2. To evaluate the safety and tolerability of EDP1815.  
 

EDP1815 -[ADDRESS_690321] to use of topi[INVESTIGATOR_531747] 4 wee ks.  Full details can be found in Section 11 Statistics .  
 
2.3. Exploratory Objectives  
The exploratory objectives of this study are the following:  
 
1. To evaluate the time to onset of clinical response to EDP1815.  
 
2. To evaluate the most effective dose and dosing frequency of EDP1815 i n the treatment of 
atopic dermatitis.  
 
3. To evaluate the effect of EDP1815 on patient reported outcomes.  
 
4. To evaluate the effect of early use of rescue therapy on Week 16 responder status.  
 
5. To evaluate the relationship of EDP1815 treatment with biomarkers such as immune 
protein markers, eosinophils, and immune cell RNA profile in blood.  
 
6.  To evaluate correlation of genetic markers and EDP1815 treatment outcomes.  
 
7. To evaluate correlation of gut microbiome and EDP1815 treatment outcomes.  
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 19 of 114 
3. STUDY V ARIABLES  
 
3.1. Efficacy Variable(s)  
3.1.1.  Primary Efficacy Variable(s)  
The primary efficacy endpoint is achievement of an EASI -50 response at Week 16.  
 
3.1.2.  Secondary Efficacy Variable(s)  
The following secondary endpoints will be evaluated at Weeks 4, 8, 12 and 16 (unless otherwise 
specified) to evaluate the maximum clinical benefit of EDP1815 in the treatment of atopic 
dermatitis:  
 
• Percentage of Participants Achieving EASI -50 [Time Frame: Week 4, 8 and 12]  
• Percentage of Participants Achieving EASI -75  
• Percentage of  Participants Achieving EASI -90  
• Mean absolute change and percentage change from baseline in EASI Score  
 
• Percentage of Participants Achieving Investigator's Global Assessment (vIGA) of 0 or 1 
with a ≥2 Point Improvement from baseline  
• Percentage of Participants Achieving vIGA of 0 or 1  
• Percentage of Participants Achieving vIGA of 0 [Time Frame: Week 16]  
• Mean absolute change and percentage change from baseline in vIGA*BSA  
• Mean absolute change and percentage change from baseline in BSA  
• Percentage of Participants Achieving BSA -50 
• Percentage of Participants Achieving BSA -75 
• Percentage of Participants Achieving BS A reduction to 3% BSA or less  
 
• Mean absolute change and percentage change from baseline in SCORing Atopic Dermatitis 
(SCORAD)  
• Percentage of Participants Achieving SCORAD -50  
• Percentage of Participants Achieving SCORAD -75  
 
• Mean absolute change and percent age change from baseline in DLQI  
• Percentage of Participants achieving a reduction of ≥4 in the DLQI, of those with a score 
of ≥4 at baseline [Time Frame: Week 16]  
 
• Mean absolute change from baseline in worst Pruritus -NRS  
• Percentage of Participants achiev ing a reduction of ≥[ADDRESS_690322] Pruritus -NRS, of those 
with a score of ≥2 at baseline  
• Percentage of Participants achieving a reduction of ≥[ADDRESS_690323] Pruritus -NRS, of those 
with a score of ≥4 at baseline [Time Frame: Week 16]  
 
• Mean absolute change from baseline in SD -NRS score  
• Percentage of Participants achieving a reduction of ≥2 in SD -NRS score, of those with a 
score of ≥2 at baseline [Time Frame: Week 16]  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 20 of 114 
• Mean absolute change and percentage change from baseline in Patient Oriented Eczema 
Measure (POEM)  
• Percentage of Participants achieving a reduction of ≥4 in the POEM score, of those with a 
score of ≥4 at baseline [Time Frame: Week 16]  
 
• Number of courses o f rescue therapy per Participant  
• Number of days of treatment with rescue therapy per Participant  
• Proportion of participants not requiring rescue therapy  
 
For secondary estimands, a treatment policy approach will be used with respect to study 
medication and a composite approach will be used for data collected within 28 days of rescue 
medication use and withdrawal from the study for reasons related to study treatment.  
 
3.2. Pharmacokinetic and Pharmacodynamic Variable(s)  
EDP1815 has no systemic absorption and therefore no systemic exposure. Therefore, no samples 
for pharmacokinetic analysis will be performed in this study.  
 
3.3. Safety Variables  
The severity and frequency of adverse events will be used to evaluate the safety a nd tolerability of 
EDP1815.  Vitals signs, weight, physical examinations, clinical laboratory tests, ECG and use of 
concomitant medications will also be used to evaluate the safety and tolerability of EDP1815.  
 
3.4. Exploratory Variables  
The following endpoints  will be used to evaluate the time to onset of clinical response to EDP1815:  
• Time to first achievement of EASI -50 
• Time to first achievement of sustained* EASI -50 
• Time to first achievement of IGA of 0 or 1 with a 2 -point improvement from baseline  
• Time to first achievement of a ≥2 point in improvement in PP -NRS score, in participants 
with a score of ≥2 at baseline  
• Time in days to first sustained** ≥2 point in improvement in PP -NRS score, in participants 
with a score of ≥2 at baseline  
• Time to first a chievement of a ≥4 point in improvement in PP -NRS score, in participants 
with a score of ≥4 at baseline  
• Time in days to first sustained** ≥4 point in improvement in PP -NRS score, in participants 
with a score of ≥4 at baseline  
• Time to first achievement of a  ≥2 point in improvement in SD -NRS score, in participants 
with a score of ≥2 at baseline  
• Time in days to first sustained** ≥2 point in improvement in SD -NRS score, in participants 
with a score of ≥2 at baseline  
* Sustained EASI -[ADDRESS_690324] two consecutive visits.  
** Sustained PP -NRS or SD -NRS response is one which is present at all days where the diary is 
completed in a minimum of a 14 -day period  
 
The following endpoints will be used to evaluate other aspects o f the efficacy of EDP1815 as a 
treatment for atopic dermatitis at Weeks 4, 12 and 16 unless otherwise specified:  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 21 of 114 
• Percentage of Participants Achieving Investigator's Global Assessment (vIGA) of 0 or 1 
with a ≥2 Point Improvement from screening  
• Mean absolut e change and percentage change from Screening in EASI Score   
• Percentage of Participants developi[INVESTIGATOR_531748] [Time Frame: Week 16]  
• Changes from baseline in SF -12 MCS and PCS scores  
• Changes from base line in HADS anxiety and depression scores  
• Changes from baseline in ADCT scores  
• Daily changes from baseline in the PP -NRS and SD -NRS [Timescale: Days 2 to 140]  
 
To evaluate the effect of early use of topi[INVESTIGATOR_531749] [ADDRESS_690325] 4, 8, 12 and 14 
weeks of treatment and to participants with  rescue therapy use within the 2 weeks and 4 weeks 
prior to the Week 16 visit.  For these subgroups, the following endpoints will be summarized:  
• Percentage of Participants Achieving EASI -50, EASI -75 and EASI -90 
• Percentage of Participants Achieving IGA 0 or 1, with and without a 2 -point improvement 
from Baseline  
• Percentage of Participants Achieving BSA -50, and BSA -[ADDRESS_690326] of EDP1815 treatment on biomarkers 
in blood at Weeks 2, 16 and 20 (unless otherw ise specified):  
• Changes from baseline in eosinophils  
• Changes from baseline in serum immune protein markers including IgE [Time Frame: 
Week 16]  
• Changes from baseline in immune cell RNA profile  

EDP1815 -[ADDRESS_690327] of 4 cohorts with a possible interim analysis pri or to end of recruitment in 
Cohorts 1, 2 & 3.  The purpose of this interim analysis is to check the assumptions around placebo 
response rate.  
 
Approximately 100 participants will be randomly allocated to each of Cohorts 1, 2, & 3.  These 
cohorts will run concurrently. Within each cohort, participants will then be randomized to 
treatment in a 3:1 ratio (75 to EDP1815, 25 to placebo).  Therefore, across Cohorts 1, 2, & 3, 
approximately [ADDRESS_690328] to participate in an 
Open Label Extension (OLE) pr otocol for EDP1815, if available.  
 
• Cohort 1:  1.6x1011 total cells of EDP1815 or matching placebo administered as 2 capsules 
once daily. 
 
• Cohort 2:  6.4x1011 total cells of EDP1815 or matching placebo administered as 2 capsules 
once daily. 
 
• Cohort 3:  6.4x1011 total cells of EDP1815 or matching placebo administered as 1 capsule 
of 3.2x1011 cells twice daily. 
 
Cohort 4  will run after enrollment is completed in C ohorts 1, 2, & 3.  A pproximately 105 
participants in this cohort will be randomized to treatment in a 2:1 ratio (70 to EDP1815, 35 to 
placebo).  Participants will be treated for [ADDRESS_690329] to participate in an 
Open Label Extension (OLE) protocol for EDP1815, if available.  
 
• Cohort 4:  8.0x1010 total cells of EDP1815 or matching placebo administered as [ADDRESS_690330] of:  
 
• Up to a 4 -week Screening Period  
 
• A 16 -week Treatment Period  
 
• A 4-week Post -Treatment Follow -up Period  

EDP1815 -[ADDRESS_690331] participant (LPLV).  
 
4.3. Planned Number of Participants  
This study will be conducted as a multi -center study at approximately [ADDRESS_690332] IMP dose wil l be given at the Day 1 visit after all procedures are completed following randomization. Subsequent doses are taken daily in  the 
morning at approximately the same time ±[ADDRESS_690333] udy visit, even if dosing 
falls outside the dosing window. Participants should refrain from consuming acidic drinks 1 hour either side of dosing and fr om eating 2 hours before 
dosing and 1  hour after dosing.  
m  Digital photographs should be taken of the u pper and lower body (upper & lower anterior and upper & lower posterior) as half body shots.  Additional 
close -up photographs of up to six specific body areas (i.e., limbs, trunk and back) will also be taken.  The same sites photographe d at Day 1 should be  
followed throughout the study for each participant.  
n AD Investigator rating scales. Participants will be asked to withhold all emollients, sunscreens, or moisturizers on the day of these study visits until all 
study assessments are completed.  
o The Pruri tus-NRS (worst itch) will be asked daily from the Screening Visit to the Week 20 Visit via a participant diary.  
p The Sleep Disturbance -NRS (SD -NRS) will be asked daily starting at the Screening Visit to the Week 20 Visit via a participant diary.  
q Adverse  Events (AE) and Serious Adverse Events (SAE) will be captured from the time the participant signs the informed consent. 
r Study staff will review the patient diary with participants at each visit. Diaries will be reviewed for completeness and accu racy, an d participants will be 
coached as needed on compliance with the protocol.  
s Patients will be asked if they have enough emollient to last them until the next study visit.  
** A fecal sample is not required for any participant that enrolls under  Protocol Version 5.[ADDRESS_690334], control 
for variables caused by [CONTACT_120373], control for other factors that can 
influence study outcomes, and finally to allow for a more complete understanding of the risk -
benefit profile of the ac tive study drug.  A position statement from the International Eczema 
Council (Leshem, et al., 2019)  has given clear guidance on the design of studies in atopic 
dermatitis, including supporting and giving a scientific rationale for  the use of placebo -control in 
studies in this condition. Placebo -controlled studies are the recommended standard. In addition, in 
this study, we are minimizing the proportion of placebo subjects by [CONTACT_2329] a 3:1 randomization ratio 
(Cohorts 1 -3) between act ive and placebo, and then pooling the placebo subjects together for 
comparison.  In Cohort 4, a 2:[ADDRESS_690335] working across Th1, 
Th2 and Th17 pathologies.   As the intent is to generate a maximal inflammation -resolving 
phenotype regardless of inflammation pathology, the dose response is expected to be common 
across indications, and therefore we aim to cross compare to previous studies to support this 
hypothesis.  A full dose -ranging study is currently being carried out in a phase 2 study (EDP -1815 -
201) in psoriasis patients.  
 
Evelo’s Phase 1 Study EDP1815 -101 evaluated EDP1815 for the treatment of atopic dermatitis 
with an oral dose of 8.0x1011 cells delivered as  ten capsules once a day for 8 weeks.   This dose was 
safe and well tolerated and clinical benefit was observed with an improvement of 50 -65% over 
placebo by [CONTACT_10585] 8 in EASI, SCORAD, and vIGA*BSA endpoints. In addition, doses of 1.6x1011 
and 8.0x1011 total cells given for [ADDRESS_690336] been investigated in this study for the treatment of 
psoriasis. Similar clinical benefit was observed at both dose levels. A Phase 2 dose ranging study 
in psoriasis (EDP1815 -201) was conducted in approximately 225 participants f or 16 weeks, at 
doses of 8.0x1010, 3.2x1011, and 8.0x1011 total cells. No evidence of dose response was seen in this 
study.  Further information on these studies is detailed in the EDP1815 Investigator’s Brochure 
(IB).  
 
The doses selected for evaluation i n EDP1815 -[ADDRESS_690337] be met:  
 
1. Must have given written informe d consent (signed and dated) and any authorizations 
required by [CONTACT_10523].  
 
2. Males or females aged ≥ 18 and ≤ 75 years old at the time of informed consent.  
 
3. A diagnosis of atopic dermatitis (AD) meeting Hani fin and Rajka criteria for AD at 
screening ( Appendix 14.1) with patient - or clinician - reported disease duration of at least 
[ADDRESS_690338] severity of atopic dermatitis meeting the below criteria at both Screening and Day 1:  
i. An IGA of 2, 3 or 4 on the vIGA scale, and;  
ii. A BSA of ≥5%, and;  
iii. An EASI score of ≥6.  
 
A cap will be set for each of the three IGA severity grades. When this cap is reached , Sponsor 
will notify sites that participants with severity score at Screening and/or Day [ADDRESS_690339] agree to use a bland additive -free, sodium lauryl sulfate (SLS) -free, 
and fragrance -free emollient cream, gel or ointment twice daily (or more, as needed) for at 
least [ADDRESS_690340] continue this 
treatment twice daily throughout the trial. See Secti on [IP_ADDRESS]. Background Therapy . 
 
6. Meet the following contraception criteria:  
i. Male participants:  
i. A male participant must agree to use contraception as detailed in Appendix 14.[ADDRESS_690341] dose and refrain from donating sperm during this period.  
ii. Female participants:  
i. A female part icipant is eligible to participate if she is not pregnant, not 
breastfeeding, and at least 1 of the following conditions applies:  
1. Not a WOCBP as defined in Appendix 14.[ADDRESS_690342] 1 complete menstrual cycle (≥30 days) after the last dose.  
 
Agrees to not increase their usual sun exposure significantly during the study.  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 32 of 114 
 
5.2. Exclusion criteria  
Participants are not permitted to enroll in the study if any of the following criteria is met:  
 
1. Atopic dermatitis limited to the hands and/or feet and/or scalp.  
 
2. Have been in a clinical trial for EDP1815 prior to signing of ICF.  
 
3. History of active skin infection within 14 days prior to randomization.  
 
4. Evidence of dermatologic conditions that may, in the opi[INVESTIGATOR_871], interfere 
with AD evaluation or the assessment of treatment response.  
 
5. Use of phototherapy or tanning beds; systemic medications/treatments that could affect AD 
or its symptoms including immunosuppressive therapy (e.g., oral or injectable 
corticosteroids, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, JAK 
inhibitors, tacrolimus, and/or leukotriene inhibitor) within 4 weeks of randomization.  
 
6. Previously received any biologic agent for AD and either was:  
a. Unresponsive to biologic agent, or  
b. Responsive to biologic agent and received this therapy within [ADDRESS_690343] atopic dermatitis, including topi[INVESTIGATOR_030], topi[INVESTIGATOR_22726] (e.g., tacrolimus or pi[INVESTIGATOR_031]), or topi[INVESTIGATOR_531750] -4 inhibitor (e.g., crisaborole) within 14 days prior to randomization.  
 
8.  Received any investigation al or licensed biologic agent for conditions other than AD:  
a. Any cell -depleting agent, including rituximab, within [ADDRESS_690344] disease (e.g., short -bowel syndrome, diarrhea -predominant irritable 
bowel syndrome) that could interfere with GI delivery and transit time.  
 
10. Active inflammatory bowel disease.  
 
11. Ongoing acute or chronic infectious disease. Patients with hepatitis B, hepatitis C, and HIV 
may be enrolled provided that the disease is adequately controlled and/or is in remission.  
 
12. Has received live or live -attenuated vaccination within [ADDRESS_690345] is 
permitted within the 28 -day screening window.  
 
14. Screening Labs: For women, serum creatinine ≥125 μmol/L (1.414 mg/dL); for men, serum 
creatinine ≥135 μmol/L (1.527 mg/dL).   
 
15. Screeni ng Labs: ALT or AST >2 × ULN.  
 
16. History of clinically significant acute cardiac or cerebrovascular event within 6 months of 
signing ICF (includes stroke, transient ischemic attack, and coronary heart disease [angina 
pectoris, myocardial infarction, heart f ailure, revascularization procedures]).  
 
17. History of active substance (drug and/or alcohol) abuse within the prior 12 months.  This 
does not include the current or prior use of cannabis.  
 
18. In the opi[INVESTIGATOR_689], evidence of clinically important cardiac conduction 
abnormalities as judged by [CONTACT_531776].  
 
19. Hypersensitivity to P histicola or to any of the excipi[INVESTIGATOR_840].  
 
20. Active mental or psychiatric disorder, which, in the opi[INVESTIGATOR_12182], 
would make the participant unsuitab le for inclusion or could interfere with the participant 
participating in or completing the study.  
 
21. Recent major surgery within 3 months of signing the ICF, or major surgery planned during 
the study.  
 
22. Malignancy within 5 years of signing the ICF, except for basal or squamous cell carcinoma 
of the skin or carcinoma in situ of the cervix that has been successfully treated.  
 
23. Treatment with another investigational drug or device within 3 months or 5 half -lives of 
investigational agent  prior to randomiz ation , whichever is longer.  
 
24. Treatment with supplements containing high doses of probiotics and prebiotics as usually 
found in capsules/tablets/powders, within 14 days prior to randomization and throughout 
the study period. Note that probiotic and prebioti c foods that contain low doses are allowed 
(e.g., yoghurt, kefir, kombucha).  
 
25. Unwillingness to comply with study procedures, including follow -up, as specified by [CONTACT_47375], or unwillingness to cooperate fully with the Investigator.  
 
26. Have any serious conditions that would be anticipated to require the use of systemic 
corticosteroids or otherwise interfere with study participation or require active frequent 
monitoring (e.g., unstable chronic asthma).  
 

EDP1815 -[ADDRESS_690346] any other conditions, which, in the opi [INVESTIGATOR_12182], would 
make the participant unsuitable for inclusion or could interfere with the participant 
participating in or completing the study.  
 
5.3. Screen Failures  
Screen failures are defined as participants who consent to participa te in the clinical study but are 
not subsequently randomly assigned to study intervention/entered in the study due to failure to 
meet eligibility criteria or failing to randomize for any reason. A minimal set of screen failure 
information is required to en sure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond 
to queries from regulatory authorities. Minimal information includes informed consent, 
demogra phy, screen failure details, eligibility criteria, and any AEs and SAEs.  
 
5.3.3.  Rescreening  
Participants who fail to satisfy inclusion and exclusion criteria at Screening may be rescreened one 
additional time with the agreement of the Medical Monitor before re -screening.   
 
A participant that is re -screened will be assigned a new participant identifier (ID).  Additional 
information on rescreening will be provided in the appropriate specific user manual.  
 
5.4. Discontinuation from Treatment and/or Withdrawal  
Participan ts may discontinue from treatment and withdraw their participation from the study at 
any time and for any reason without prejudice to their future medical care by [CONTACT_531777]. Every effort should be made to keep participants in th e study. The reasons for 
participants discontinuing treatment and withdrawing from the study will be recorded in the source 
files and on the eCRF.  
 
Interruption of treatment  is defined as a temporary stoppi[INVESTIGATOR_531751] d, due to an AE or any other reason. The maximum permitted interruption at one 
time is 7 days and the participants should not interrupt IMP for more than 14 days in total.  
 
Early discontinuation of treatment  is defined as permanent stoppi[INVESTIGATOR_531752]  16 
visit. Investigators will strive to ensure that a participant who has interrupted treatment for a 
particular reason will not discontinue IMP unless discontinuation is medically imperative in the 
Investigator’s judgment. However, a dose interruption of more than 7 days or multiple dose 
interruptions totaling more than 14 days will result in mandatory discontinuation of IMP and early 
termination of the participant.  
 
Early withdrawal from the study  is defined as failing to complete the 16 -week treatment and the 
4-week follow -up period unless the participant transitions to the Open Label Extension (OLE) 
Protocol at Week 16.  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 35 of 114 
 
A participant will discontinue IMP and be withdrawn from the study for  any of the following 
reasons:  
 
1. The participant experiences treatment failure, demonstrated by [CONTACT_531778], an oral agent, biological, or intermediate or high -potency topi[INVESTIGATOR_531753].  
 
2. The participant has a serious or intolerable AE that in the Investigator’s opi[INVESTIGATOR_531754].   
 
NB: Dosing may be interrupted at the Investigator’s discretion due to AE or intercurrent 
illness for a period of up to [ADDRESS_690347] to follow -up. 
 
5. Other rea sons (e.g., pregnancy, development of contraindications to use of IMP).  
 
6. The participant withdraws consent, or the Investigator or Sponsor decides to discontinue the 
participant’s participation in the study.  
 
A participant may discontinue IMP and be withdrawn from the study for any of the following 
reasons:  
 
1. The participant is noncompliant with the protocol.  
 
2. The participant has laboratory safety results that reveal clinically significant hematological 
or biochemical changes fr om the baseline values.  
 
3. If the participant is required to start therapy for a concurrent condition that may affect the 
study endpoints, e.g., a disease modifying agent for asthma.  
 
Investigators should contact [CONTACT_1689], whenever possible, to di scuss the treatment 
discontinuation and withdrawal of a participant in advance of this decision.  
 
Investigators should attempt to obtain information on participants in the case of treatment 
discontinuation and withdrawal.  All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the participant, must be recorded in the source 
documents. The CRF must document the primary reason for treatment discontinuation and 
withdrawal.  

EDP1815 -[ADDRESS_690348] or they may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or 
administrative reasons. The Investigator w ill also withdraw a participant if Evelo terminates the 
study.  
 
If the participant withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.    
 
If a participa nt withdraws from the study, he/she may request destruction of any samples taken and 
not tested, and the Investigator must document this in the source and eCRF.  
 
The participant randomization number accounts for an expected drop -out rate of approximately 
20%.  
 
The drop -out rate within each treatment group will be estimated during the interim analysis.  
Should [ADDRESS_690349] a drop -out rate of 25% or more, additional 
participants will be randomized.  
  
5.4.2.  Lost to Follow -Up 
A partic ipant will be considered lost to follow -up if s/he repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_9298].  
 
The following actions must be taken if a participant fails to return to the study site for a required 
study  visit:  
 
• The site must attempt to contact [CONTACT_197651]/or sh ould continue in the 
study.  
 
• Before a participant is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 2 telephone calls and, if 
necessary, a written message to the partici pant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_322437] (date and 
summary of the phone call and copy of the written message in the source documents).  
 
If the participant continues to be unreachable, s/he will be considered to have withdrawn from the 
study.  
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 37 of 114 
6. STUDY TREATMENT(S)  
 
6.1. Investigational Medicinal Product(s)  
Investigational Medicinal Product (IMP) is defined as any investigational treatment(s), marketed 
product(s), placebo, or medical device(s) intended to be administered to a study participant 
according to the study protocol.  
 
All IMP in this study will be administered orally. EDP1815 will be supplied as capsules that are 
enteric -coated to release the contents upon gastric empt ying. EDP1815 enteric -coated capsules 
contain lyophilized Prevotella histicola , mannitol, magnesium stearate, colloidal silicon dioxide, 
hydroxypropyl methylcellulose, methacrylic acid -ethyl acrylate copolymer, talc, triethyl citrate, 
titanium dioxide, and  iron oxide .  
 
EDP1815 capsules will be manufactured in the following dose strengths and associated enteric 
coating thickness (EC) .  The thickness of the capsule enteric coating for Cohort 4 is thinner (EC2) 
than the capsule enteric coating for Cohorts 1, 2, & 3 (EC1):  
 
Cohort 1:   8.0x1010 total cells per capsule (EC1)  
Cohort 2 & 3:  3.2x1011 total cells per capsule (EC1)  
Cohort 4:   8.0x1010 total cells per capsule (EC2)  
 
The drug substance used in Cohorts [ADDRESS_690350](s) to be Administered  
The study IMP (EDP1815 or placebo) will be administered as capsules for 16 weeks in total.   
 
Study IMP is to be taken with water at approximately the same times each day ( ±2 hours, whenever 
possible). With twice daily dosing, administration should be in the morning and evening, with the 
doses separated by [CONTACT_3450] 12 hours ( ±2 hours, whenever possible).  
 
Participants should refrain from consuming acidic drinks (such as cola/soda, coffee, sports and 
energy drinks, flavored  waters and citrus juices) 1 hour either side of dosing and from eating 2 
hours before and 1 hour after dosing.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 39 of 114 
The Investigator (or designee) will instruct the participant to store the IMP following the 
instructions on the label.  
 
6.6. IMP Accountability  
An Interactive Response Technology (IRT) system will be used to record IMP dispensing and 
return information on a by -participant basis during the study. Details of any IMP lost, damaged 
(due to breakage or wastage), not used, partially used, disposed of at the study site, or returned to 
the Sponsor or designee must also be recorded. All supplies and pharmacy documentation mu st be 
made available throughout the study for the Sponsor (or designee) to review.  
 
Participants will utilize an electronic diary (eDiary) to record their IMP intake on a daily basis 
(Section 6.6.1  eDiary ). 
 
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.  
 
The Investigator may assign some of t he Investigator’s duties for IMP accountability at the study 
site to an appropriate pharmacist/designee.  
 
The Investigator must ensure that the IMP is used only in accordance with the protocol.  
 
All used (including empty containers)/partially used, unused,  damaged, and/or expi[INVESTIGATOR_531755], and Sponsor SOPs, if applicable.  Investigational medicinal 
product intended for the st udy cannot be used for any other purpose than that described in this 
protocol.  
 
6.6.1.  eDiary  
The primary purpose of the diary is to enhance participant compliance with the protocol.  All 
participants will be provided with a paper participant diary at the Screeni ng Visit to record their 
emollient use and daily PP -NRS and SD -NRS scores prior to the Day 1 Visit.  The participants 
will then utilize an electronic diary (eDiary) commencing upon completion of the Day 1 Visit 
through the Week 20 Follow -Up Visit.  The eDi ary will be an application (app) that will be 
downloaded to the participant’s mobile smartphone, and for those participants that do not have a 
mobile smartphone or do not wish to download an app to their phone, they will receive an eDiary 
device specifical ly designated for the purpose of collecting information as described below.  
Participants will be asked to capture the following information in their eDiary:  
• Study IMP  
o Confirmation of dosing  
o Date and time of dosing  
o Number of capsules taken, with reasons n ot taken, if applicable.  
• Background Therapy (Emollient(s))  
o Frequency of usage (number of times a day)  
• Rescue Therapy Usage  
o Confirmation of usage  
• Daily Peak Pruritus Numerical Rating Scale (PP -NRS)  

EDP1815 -[ADDRESS_690351] itch over previous 24 -hour period  
• Daily Sleep Disturbance Numerical Rating Scale (SD -NRS)  
o Evaluation of worst sleep over previous [ADDRESS_690352] the participants to uninstall the eDiary 
application on their mobile smartphone devices and/or collect any eDiary devices that were 
distributed to the participants.  
 
6.7. Drug Compliance  
Participants will use the eDiary to capture compliance with their study IMP.  At specified visits 
per the Schedule of Activities (SOA), the study site staff will check numbers of used/unused 
capsules a gainst diary entries and remind the participant of the need to self -administer the capsules 
as directed, and to store the IMP according to label instructions.  
 
Prior to the specified study visits per the SOA, study site staff will call participants to remi nd them 
to bring all empty IMP wallets and cartons in the original containers to the study site for their visit.  
If a participant is found to be persistently noncompliant, the Sponsor, in conjunction with the 
Investigator, will decide as to whether the par ticipant should be withdrawn from the study.  
 
6.8. Dose Modification  
Dose adjustments, including dose interruptions, and/or decreasing the dose frequency may be 
allowed for safety or tolerability after consultation with the Medical Monitor.  The maximum 
permitted interruption at one time is 7 days and the participants should not interrupt IMP for more 
than 14 days in total.  
 
6.9. Concomitant Medications and Treatments  
Throughout the study, the participant may be prescribed concomitant medications or treatments 
deemed necessary to provide adequate supportive care at the discretion of the Investigator provided 
that the medications are licensed.  However, it is the responsibility of the Investigator to ensure 
that details regarding the medication are rec orded in full in the eCRF.  
 
All concomitant medications and/or treatments received by a participant should be recorded on the 
appropriate source document and eCRF with the following minimum requirements:  
• Drug trade name  
• Total daily dose  
• Dates of administra tion   
• Reason for use (indication)  
• Dosage information (including dose and frequency)   
 
This will include all prescription drugs, herbal products, vitamins, minerals, over -the-counter 
(OTC) medications, and vaccines.  Any changes in concomitant medications  also will be recorded 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 41 of 114 
in the participant’s eCRF.  The participant’s dosing diary may contain information relevant to the 
documentation of changes in concomitant medication.  
 
6.9.1.  Permitted Concomitant Medications and Treatments  
The following concomitant medica tions are permitted for use during the study:  
• Concomitant medications for conditions other than AD may continue throughout the trial, 
if not meeting any exclusion criteria, and should continue without change in dosage or 
formulation whenever possible.  
• New therapy/treatments, not expected to have any impact on AD, but deemed necessary 
for the welfare of the participant during the study, are permitted. If there is doubt about 
their impact on AD or ability to continue in the study, then this should be discusse d with 
the Medical Monitor.  
• Topi[INVESTIGATOR_190734] (For suspected skin infection, see Section [IP_ADDRESS]  Rescue 
Therapy)  
• All participants  must use an emollient twice daily for at least 14 consecutive days prior to 
Day 1 and throughout the study ( Section [IP_ADDRESS]  Background Therapy) . 
• Topi[INVESTIGATOR_190734], antiviral, or antifungal therapy.  
• Oral antihistamines.  
• Nasal, inhaled and ophthalmic corticosteroids.  
• Non-replicating / Non -live vaccines ( Section 6.9.3  Immunizations) . 
 
[IP_ADDRESS].  Background Therapy  
All participants  must use an emollient twice daily to all body areas for at least [ADDRESS_690353] be a bland emollient which is additive -free, SLS-
free, and fragrance -free and may be in cream, gel or ointment formulation.  Whenever possible, the 
same brand and formulation of emollient should be used throughout the study by a participant. 
Participants are not allowed to use emollients containing additives (e.g., urea, ceramide, 
nicotinamide). Participants should continue thi s background emollient treatment twice daily until 
the Week [ADDRESS_690354] 75% of the expected a pplications during the study. Participants need to meet 
this criterion within the 14 days prior to randomization in order to be randomized (i.e., 21 
applications of emollient out of the previous 28 applications (14 days) immediately prior to Day 
1). Otherw ise, participants may be considered for re -screening.  
 
If a participant is found to be persistently noncompliant, the Sponsor, in conjunction with the 
Investigator, will decide as to whether the participant should be withdrawn from the study.  
 
Background t herapy between Screening and Randomization will be recorded via a paper diary.  
Participants will record their background therapy via the participant eDiary from Day 1 to the 
Week 20 Follow -Up Visit ( Section 6.6.1  eDiary ). 
 

EDP1815 -[ADDRESS_690355] the Medical Monitor to discuss any questions on the use of background therapi[INVESTIGATOR_014].  
 
[IP_ADDRESS].  Rescue Therapy  
If required, Investigators may prescribe / recommend prescription of r escue therapy for 
participants experiencing unacceptable worsening of atopic dermatitis. Additionally, individuals 
with uncontrolled atopic dermatitis could be at risk for a secondary skin infection.  These 
participants may be prescribed an antimicrobial t herapy to treat the infection as detailed below. 
Rescue therapy use is allowed throughout the entire study. There is no limit on the number of times 
that topi[INVESTIGATOR_531756], although Investigators and participants may wish to 
consider  whether the study is suitable for them if repeated courses are required.  
 
Rescue therapy, including antimicrobial rescue therapy, should be prescribed as detailed below, 
and any specific deviations should first be discussed with the Medical Monitor. Parti cipants 
rescued by [CONTACT_531779][INVESTIGATOR_531757] ( Section 6.6.1  eDiary ). Of note, Investigators should make 
every attempt to conduct the following assessments immediately prior to administering any rescue 
therapy, by [CONTACT_531780], if needed:  
• EASI  
• vIGA  
• PP-NRS  
• AEs 
• Concomitant Medications  
 
For non-sensitive body sites:  
• Moderate potency (grade IV and V – Appendix 14.2) topi[INVESTIGATOR_11930], twice daily 
for up to 7 days  
 
For sensitive site s e.g., head and neck:  
• Topi[INVESTIGATOR_22777] (0.1%), topi[INVESTIGATOR_119024] (1%) or grade VII topi[INVESTIGATOR_11977], 
twice daily for up to 7 days  
 
If topi[INVESTIGATOR_531758], then the participant should be 
considered for alt ernative systemic therapy or phototherapy by [CONTACT_737]/their practitioner, 
at which point they will be classified as a treatment failure and IMP will be discontinued.  
 
For possible skin infection:  
• Topi[INVESTIGATOR_2855]:  
o Appropriate courses of topi[INVESTIGATOR_531759] l therapi[INVESTIGATOR_014], such as fucidic acid cream 
(e.g., Fucidin), are acceptable for use for skin infections, as required  
o If requiring concomitant moderate potency steroid therapy, fucidic acid with 
betamethasone 0.1% (as the valerate ester), (e.g., Fucibet cream) twice daily for up 
to 7 days  
• Oral:  
o Appropriate course(s) of oral antibiotic(s) may be prescribed as per clinical need  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 43 of 114 
6.9.2.  Prohibited Concomitant Medications and Treatments  
 
[IP_ADDRESS].  Prohibited Concomitant Medications  
The following concomitant medications are prohibited during the study:  
• Live (attenuated) vaccinations: not permitted at any point during the study ( Section 6.9.3  
Immunizations).  
 
[IP_ADDRESS].  Discontinuati on of Prohibited Concomitant Medications  
Use of any of the following concomitant medications during the study require the concomitant 
medication to be immediately discontinued where possible. If the prohibited medication cannot be 
discontinued for any reas on, then the IMP should be discontinued:  
• Emollients containing additives including SLS  
• Topi[INVESTIGATOR_531760] (unless used as Rescue Therapy, 
Section [IP_ADDRESS]  Rescue Therapy ) 
• Topi[INVESTIGATOR_22732] -4 Inhibitors  
• Bleach baths  
• Tanning beds  
• Leukotriene Receptor Antagonists  
• Allergen Immunotherapy  
 
[IP_ADDRESS].  Prohibited Concomitant Medications Requiring IMP Discontinuation  
Introduction of any of the following concomitant medications during the study will be classified 
as a treatment failure and require IMP discontinuation:  
• Phototherapy treatment  
• Systemic treatments that may lead to clinical improvements in atopic dermatitis,  e.g., oral 
or injectable corticosteroids, methotrexate, azathioprine, cyclosporine, mycophenolate 
mofetil, JAK -inhibitors , biologic therapy, and o ther systemic immunosuppressive therapy 
(note single dose intra -articular or intra -lesional corticosteroid th erapy is permitted).  
 
6.9.3.  Immunizations  
Non-replicating / Non -live vaccines are permitted during the study.  This includes all SARS -CoV -
2 (COVID) non -live vaccines and non -replicating vaccines.  However, the first dose of IMP should 
not be taken within a 7 -day window of administration of the vaccine.  
 
Live (attenuated) v accinations are not permitted at any point during the study. This includes 
vaccines for measles, mumps, rubella, vaccinia, varicella, zoster (which contains the same virus as 
varicella  vaccine  but in much higher amount), yellow fever, rotavirus, and influe nza (intranasal).  
The non -intranasal seasonal flu vaccine is permitted, as is the recombinant zoster vaccine (non -
live).  
 
6.10. Blinding  
Cohort assignments will not be blinded however, assignment to IMP within a cohort will be 
blinded. All IMP within a cohort ( EDP1815 and matching placebo) will be supplied in identical 
packaging, color, smell, and appearance to enable double -blinded conditions that ensure all 
Investigators, study site staff, participants, and clinical monitors will remain blinded throughout 
the study.  The IRT system will assign IMP to participants at the time of randomization.  Only 

EDP1815 -[ADDRESS_690356] access to treatment assignments; all o ther parties involved in the 
study will be fully blinded.  
 
For the interim analysis  just before the end of recruitment to Cohorts 1,  2 & 3, unblinded aggregate 
results will be produced by [CONTACT_531781] (external to Evelo) and reviewed by [CONTACT_531782] . These will not be shared with any study site staff, participants, or any members of the 
study team who will be involved in the collection, review o r analysis of individual study data.  
 
6.10.1.  Breaking the Blind  
A participant’s treatment assignment will not be unblinded for the Investigator or study site staff 
until end of study unless medical treatment of the participant depends on knowing the study 
treatment the participant received. In the rare event that unblinding is needed because of a medical 
emergency, the Investigator may unblind an individual participant’s treatment allocation through 
the IRT. In case of an emergency, the Investigator has the  sole responsibility for determining if 
unblinding of a participant’s study treatment assignment is warranted. Participant safety must 
always be the first consideration in making such a determination. If the Investigator decides that 
unblinding is warrante d, the Investigator should make every effort to contact [CONTACT_531783] a participant’s study treatment assignment unless this could delay emergency 
treatment of the participant. If a participant’s study treatment assignment is unbl inded, the Medical 
Monitor must be notified within [ADDRESS_690357] also be documented.  
 
Participants who are unblinded will be allowed to continue their participation in the study; 
however, any data collected after the unblinding occurred may be excluded from one or more of 
the defined data point se ts. 
 
The Clinical Safety Team at will be unblinded to study treatment to facilitate appropriate 
identification and reporting of S[LOCATION_003]Rs to Competent Authorities and the relevant IECs/IRBs.  
 
6.11. Randomization  
An IRT will be used for assigning eligible p articipants to a cohort (as applicable) based on a 
predetermined production randomization and/or packaging schedule. The randomization schedule 
will be produced by [CONTACT_352240]. The IRT will generate individual assignments for participant 
kits of IMP, as  appropriate, according to the visit schedule.  
 
To randomize a participant, the Investigator or designee will contact [CONTACT_531784]. The IRT will assign a participant randomization 
number. The IRT will allocate kit numbers to the participant based on the participant number 
during the course of the study. The kit number may be incorporated into the CRF.  
 
The randomization schedule will be stratified by [CONTACT_531785] [ADDRESS_690358] to disease severity.  The 
randomization schedule for Cohort 4 will also be stratified by [CONTACT_531785] 1. In order to match as 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 45 of 114 
closely as possible the severity of Cohorts 1,  2 & 3. Cohort 4  may also limit the numbers of 
participants recruited to each strata to match the proportions of each vIGA strata in Cohorts 1,  2 
& 3.  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 46 of 114 
7. STUDY PROCEDURES BY [CONTACT_531786] (I CF).   
 
Visit windows are consecutive calendar days and the target visit dates are calculated from the Day 
1 visit.  
 
The Schedule of Activity (SOA) is presented in Table [ADDRESS_690359] not been any adverse reactions.  
 
7.1. Screening Visit  
At the time of Screening, each site will sequentially assign a unique identifier to each participant 
which will be used for the duration of the study.   
 
The following procedures will be performed at the Screening Visit  to determine the participant’s 
eligibility for the study:  
• Obtain written informed consent from participant  
• Assess inclusion and exclusion criteria  
• Collect demographics including year of birth, age, gender, race, and ethnicity.  
• Obtain medical history including onset year of AD and the participant’s smoking status  
• Perform full physical examination  
• Measure vital signs (blood pressure, heart rate, respi[INVESTIGATOR_7146]) including 
height and weight  
• Perform 12 -lead electrocardiogram (ECG)  
• Collect blood for screening labs  
• Collect urine for screening urinalysis  
• Perform serum pregnancy test for women of child -bearing potential (WOCBP)  
• Determine the Investigator’s Global Assessment (vIGA) Score  
• Perform EASI rating scale and determine BSA involvement (%)  
• Review and document concomitant medications and therapi[INVESTIGATOR_014]  
• Assess and document adverse events (AEs) that occur after participant signs informed 
consent form (ICF)  
• After the participant has completed all screening activities, provide them the  Patient Skin 
Care Instructions for emollient, as well as paper diaries for recording emollient use and the 
PP-NRS and SD -NRS scores.  
 
7.2. Day [ADDRESS_690360] 14 consecutive days prior to 
randomization wi th a minimum compliance of 75% total applications (minimum of 21 out of the 
28 applications in the 14 days prior to day 1). On the day of the Day [ADDRESS_690361] been performed ( Section [IP_ADDRESS]  
Background Therapy) . 

EDP1815 -[ADDRESS_690362] within 28 days of the Screening Visit.  The following procedures 
will be performed:  
• Review inclusion and exclusion criteria  
• Perform full physical examination  
• Measure vital signs including weight  
• Collect blood for safety labs as well as serum immune  protein markers and inflammatory 
markers  
• Collect urine for urinalysis  
• Perform urine pregnancy test for WOCBP  
• Take digital photographs of the upper and lower body (anterior and posterior) as half body 
shots.  Additional photographs of up to six specific bo dy areas, i.e., limbs, trunk and back 
(excluding scalp, genitals and any identifying features) may also be taken.   
• Perform AD rating scales - vIGA, EASI (and BSA), and SCORAD  
• Perform patient reported clinical rating scales – HADS, POEM, DLQI, ADCT, and SF -12 
• Review and document concomitant medications and therapi[INVESTIGATOR_531761]  
• Assess and document adverse events (AEs)  
• OPTIONAL: If participant consented to genetic testing, collect appropriate blood sample  
 
Randomization Procedures  
• Randomize the participant in IRT after all Day 1 activities are completed and the participant 
is still deemed eligible to participate  
• Administer the first dose of IMP  
• Dispense IMP to cover the first 4 weeks of the treatment period  
• Assist participant in mo bile app installation on their smartphone device and provide 
instructions on completion of eDiary  
 
7.3. Week [ADDRESS_690363] 14 days (±3 days) after the Day [ADDRESS_690364] been performed.  See Section [IP_ADDRESS]  Background Therapy . 
 
The following procedures will be performed:  
• Perform brief physical examination  
• Measure vital signs  
• Collect blood for safety labs as well as inflammatory markers  
• Collect urine f or urinalysis  
• Perform AD rating scales - vIGA, EASI (and BSA), and SCORAD  
• Perform patient reported clinical rating scales – POEM, and DLQI  
• Review and document concomitant medications and therapi[INVESTIGATOR_531761]  
• Assess and document adverse events (AEs)  
• Confirm patient is taking IMP per protocol and is recording this via the eDiary  
• Dispense IMP to cover the next [ADDRESS_690365] 28 days (±3 days) after the Day [ADDRESS_690366] been performed.  See Section [IP_ADDRESS]  Background Therapy . 
 
The following procedures will be performed:  
• Perform brief physical examination  
• Measure vital signs including weight  
• Perform 12 -lead ECG  
• Collect blood for safety labs  
• Collect urine for urinalysis  
• Perform urine pregnancy test for WOCPB  
• Take digital photographs of the same body locations taken at the Day 1 Visit  
• Perform AD rating scales, including vIGA, EASI (and BSA), an d SCORAD  
• Perform patient reported clinical rating scales – HADS, POEM, DLQI, ADCT, and SF -12 
• Review and document concomitant medications and therapi[INVESTIGATOR_531761]  
• Assess and document adverse events (AEs)  
• Confirm patient is taking IMP per proto col and is recording this via the eDiary  
• Collect empty and unused study wallets/cartons dispensed at the Day 1 Visit  
• Dispense IMP to cover the next [ADDRESS_690367] 56 days (±3 days) after the Day [ADDRESS_690368] be en performed.  See Section [IP_ADDRESS]  Background Therapy . 
 
The following procedures will be performed:  
• Perform brief physical examination  
• Measure vital signs  
• Collect blood for safety labs  
• Perform urine pregnancy test for WOCBP  
• Perform AD rating scales, including vIGA, EASI (and BSA), and SCORAD  
• Perform patient reported clinical rating scales – POEM, and DLQI  
• Review and document concomitant medications and therapi[INVESTIGATOR_531761]  
• Assess and document adverse events (AEs)  
• Confirm patient is taking IMP per protocol and is recording this via the eDiary  
• Dispense IMP to cover the last [ADDRESS_690369] 84 days (±3 days) after the Day [ADDRESS_690370] been performed.  See Section [IP_ADDRESS]  Background Therapy . 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 49 of 114 
 
The following procedures will be perf ormed:  
• Perform brief physical examination  
• Measure vital signs  
• Collect blood for safety labs  
• Perform urine pregnancy test for WOCBP  
• Take digital photographs of the same body locations taken at the Day 1 Visit  
• Perform AD rating scales, including vIGA, EASI  (and BSA), and SCORAD  
• Perform patient reported clinical rating scales – HADS, POEM, DLQI, ADCT and SF -12 
• Review and document concomitant medications and therapi[INVESTIGATOR_531761]  
• Assess and document adverse events (AEs)  
• Confirm patient is taking IMP per protocol and is recording this via the eDiary  
 
7.7. Week [ADDRESS_690371] 113 days (±3 days) after the Day [ADDRESS_690372] been performed. See Section [IP_ADDRESS]  Background Therapy . 
 
The following procedures will be performed:  
• Perform full physical examination  
• Measure vital signs including weight  
• Perform 12 -lead ECG  
• Collect blood for safety labs as well as serum immune protein markers and inflammatory 
markers  
• Collect urine for urinalysis  
• Perform urine pregnancy test for WOCBP  
• Take digital photographs of the same body locations taken at the Day 1 Visit  
• Perform AD rati ng scales, including vIGA, EASI (and BSA), and SCORAD  
• Perform patient reported clinical rating scales – HADS, POEM, DLQI, ADCT and SF -12 
• Review and document concomitant medications and therapi[INVESTIGATOR_531761]  
• Assess and document adverse events (A Es)  
• Confirm patient took IMP per protocol and recorded this via the eDiary  
• Collect all remaining empty and unused study wallets/cartons dispensed at the Week 2, 
Week [ADDRESS_690373] the option to enter an 
Open Label Extension (OLE) protocol at the Week [ADDRESS_690374] be signed prior to the Week 16 Visit, however, only those participants that complete all 16 
weeks  on study IMP (active or placebo) will be allowed to participate in the OLE.  
 
Participants who do not enroll into the OLE will enter a [ADDRESS_690375] 141 days (+3 days) after the Day [ADDRESS_690376] 
been performed.  See Section [IP_ADDRESS]  Background Therapy . 
 
The following procedures will be performed:  
• Perform brief physical examination  
• Measure vital signs including weight  
• Perform 12 -lead ECG  
• Collect blood for safety labs as well as inflammatory markers  
• Collect urine for urinalysis  
• Perform urine pregnancy test for WOCBP  
• Take digital photographs of the same body locations taken at the Day 1 Visit  
• Perform AD rating scales, including vIGA, EASI ( and BSA), and SCORAD  
• Perform patient reported clinical rating scales – HADS, POEM, DLQI, ADCT, and SF -12 
• Review and document concomitant medications and therapi[INVESTIGATOR_531761]  
• Assess and document adverse events (AEs)  
• Assist the participant to uninstall the mobile application from their smartphone device  
 
7.9. Early Termination Visit  
Participants who withdraw prematurely from the study should have an early termination visit using 
the Early Termination Visit schedule within [ADDRESS_690377] a final telephone call 28 days (+3 days) after taking their last dose of 
IMP for safety as sessments. The date of this telephone call will be considered the end of study date 
for these participants.  
 
7.10. Unscheduled Visits  
Unscheduled visits are visits that fall outside of the scheduled visits indicated in the SOA.  These 
visits and the findings ar e to be recorded on the appropriate eCRFs.   
 
If an unscheduled visit occurs due to the participant requiring rescue therapy, every attempt should 
be made to conduct efficacy and safety assessments (e.g., EASI, BSA, vIGA, AEs, and 
concomitant medications) immediately before prescribing/administering any rescue therapy 
[Section [IP_ADDRESS]  Rescue Therapy] . 
 
7.11. COVID -[ADDRESS_690378] been 
considered, for example, the scenarios of individual self -isolation or local/national lockdo wn. 
 
7.11.1.  EDP1815 and Risk of COVID -19 Infection  
EDP1815 does not broadly impair either innate or adaptive immune responses, as detailed in a full 
risk-assessment in Appendix 14.4.  Anti -viral responses such as cytotoxic T -cell production of 
interferon -gamma, innate anti -viral production of interferon -alpha and interferon -beta, and the 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 51 of 114 
generation of high -affinity antibodies are all preserved pre -clinically after treatment with 
EDP1 815. There is no pre -clinical or clinical evidence of EDP1815 causing immunosuppression.  
 
EDP1815 was investigated as a treatment of patients hospi[INVESTIGATOR_363095] -19 infection (study 
reference: EDP1815 -204 and EDP1815 -205), but no safety or efficacy dat a have yet been reported 
from these studies.  
 
7.11.2.  EDP1815 and COVID -[ADDRESS_690379] may not be a reason in itself to stop 
dosing, as EDP1815 is not expected to increase the risks associated with COVID -19. If  a study 
participant is diagnosed with COVID -19 infection (diagnosed clinically or by [CONTACT_306900]), the 
participant may continue study treatment if the Investigator considers that there is a positive 
individual risk/benefit balance. This should be dis cussed with the Medical Monitor.  
 
[IP_ADDRESS].  COVID -[ADDRESS_690380] self -isolate or quarantine while on study, and a study visit 
coincides with this self -isolation or quarantine, the study visit will be missed and the reason the  
visit was not done recorded in the source documents with COVID -19 isolation / lockdown as the 
reason for the visit not completed.   
 
In lieu of the study visits, the participant may receive a telephone call to assess adverse reactions, 
ascertain study IMP  status (i.e., did the participant self -interrupt taking IMP) and emollient usage, 
and collect information on any concomitant medications, including any rescue therapy.  
Information should be recorded in the participant’s source documents and entered into the EDC, 
as applicable.  
 
The Week 16 study visit should not be missed wherever possible; these visits, therefore, may be 
conducted outside of the protocol study window.  Please contact [CONTACT_531787].   
 
7.12. Missed Visits and Procedure s 
Missed visits and any procedures not performed (not attempted) for reasons other than screen 
failure, illness, injury or progressive disability (i.e., subject is physically unable to perform test) 
will be reported as protocol deviations.  
 
A major protocol deviation will be recorded for missed visits and any procedures not performed 
(not attempted) for Day 1 and Week 16 visits, regardless the reason the visit was missed.   
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 52 of 114 
Procedures or visits not performed due to screen failure, illness, i njury or disability, including 
procedures that were attempted but failed (i.e., blood samples unable to be drawn after multiple 
attempts) will not be reported as protocol deviations.  
 
  

EDP1815 -[ADDRESS_690381] medical history (including diagnosis of atopic dermatitis), 
as well as concomitant medication usage.  
 
All efficacy assessments will be completed at the study site utilizing a site tablet at the specified 
visits as indicated on the SOA.  The site staff will assist the participant in completing those 
assessments that a re considered patient reported outcomes (PRO). The same reviewer should 
conduct the skin assessments wherever possible for a single participant, and if not possible, at a 
minimum, the same reviewer performs the Day 1 and Week 16 assessments for that partic ipant.   
 
The Investigators and site staff will be provided with further details on how to perform the 
following assessments and how to calculate each of the scores (if applicable).   
 
8.1. Eczema Area and Severity Index  
The Eczema Area and Severity Index (EASI ) is a validated measure of eczema severity, which 
considers a combination of the body surface area affected across 4 body regions, and the severity 
of the clinical signs of erythema, oedema/induration, excoriation and lichenification (Eczema, 
n.d.). The EASI score ranges from 0 – 72 (EASI, 2017 Jan) . EASI -50, EASI -75, EASI -[ADDRESS_690382] 50%, 75% and 90% decrease from baseline EASI score 
respectively.  
 
EASI is the core outcome for measuring the clinical signs of AD in all AD trials, as selected by 
[CONTACT_531788] (HOME) group. The EASI score will be assessed 
to determine the treatment effect of EDP1815 compared to placebo.   
 
8.2. Validated Investigator’s Glob al Assessment  
The Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA) will be used to 
describe the overall appearance of lesions at a given time -point (Simpson E, 2020 Sep) . There is a 
standardised gradin g system based on an overall assessment of the degree of erythema, 
papulation/induration, lichenification, and oozing/crusting. In indeterminate cases, extent will be 
used to differentiate between scores – but otherwise extent is not used in the scoring sy stem. The 
vIGA score ranges from 0 (Clear skin) to 4 (Severe disease).  
 
8.3. SCORing Atopic Dermatitis  
The SCORing Atopic Dermatitis (SCORAD) is a clinical tool which is also used to assess the 
extent and severity of eczema, to assess treatment effects. There i s an investigator -rated area score 
which uses the rule of nines to assess disease extent, and a disease intensity score comprising 
erythema, swelling, oozing/crusting, excoriation, lichenification, and dryness. Additionally, there 
is a subjective symptoms component which considers itch and sleeplessness scored using a visual 
analogue scale. These scores combine to give a SCORAD score between 0 – 103 (Dermatitis, 
1993) . 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 54 of 114 
8.4. Patient Oriented Eczema Measure  
The Patient Oriented Eczema Measure (POEM) is a simple PRO assessment tool for monitoring 
disease severity.  It includes a series of 7 questions, measuring itch, sleep, bleeding, 
weepi[INVESTIGATOR_007]/oozing, cracking, flaking, and dryness/roughness over the last week, and is scored by [CONTACT_2416].  Each of the 7 questions is scored from 0 (no days) to 4 (every day), giving a POEM 
score range from 0 to 28, with higher scores representing higher disease severity (Charman, 2004 
and Charman, 2013). The minimally clinica lly important difference threshold is a change of ≥3.4 
points on average  (Schram, et al., 2011) . For the purposes of changes within an individual 
participant, a response will therefore be considered to be a ≥4 -point change from  baseline.  
 
8.5. Dermatology Life Quality Index  
This is a validated patient reported outcomes instrument comprised of 10 questions to assess how 
a participant’s skin disease has affected their quality of life over the past week (Finlay A Y, 1994) . 
The DLQI score ranges from [ADDRESS_690383] on a patient’s quality of life, and 
a 4-point change from baseline is considere d the minimal clinically important difference threshold 
(Basra, 2015) . 
 
8.6. Peak Pruritus Numerical Rating Scale (PP -NRS)  
The Peak Pruritus Numerical Rating Scale (PP -NRS) is a scale from 0 (“no itch”) to 10 (“worse 
imaginable itch”) for participants to rate their worst itch that they have experienced over the 
previous 24 hours (Phan, 2011) .  The  PP-NRS will be completed daily question via a daily 
questionnaire from the Screening Visit to the Week 16 visit. A ≥2 -4-point change from baseline is 
considered the minimally clinically important difference threshold (Yosipovitch, et al., 2019) . 
 
8.7. Sleep Disturbance Numerical Rating Scale (SD -NRS)  
The Sleep Disturbance Numerical Rating Scale (SD -NRS) is a scale from 0 (“best possible sleep”) 
to 10 (“worse possible sleep”) for participants to rate their worst sleep that they have  experienced 
over the previous 24 hours. The SD -NRS will be completed via a daily questionnaire from the 
Screening Visit to the Week 16 visit. A ≥2 point change from baseline is considered the minimally 
clinically important difference threshold (Dias -Barbosa, Matos, & Vernon, 2020) . 
 
8.8. Body Surface Area  
The Body Surface Area (BSA) is a measure of the extent of atopic dermatitis at a given time. It is 
calculated by [CONTACT_531789]’s handprints of active atopic dermatitis are 
present where one handprint (including digits) represents 1% body surface area. The BSA provides 
another assessment of disease severity by [CONTACT_531790] a product of the vIGA*BSA as a furthe r marker of disease severity and response to 
treatment (Suh, 2020) . 
 
8.9. 12-Item Short Form Health Survey  
The 12 -Item Short Form Health Survey (SF -12) is a PRO instrument consisting of twelve questions 
used to measure non -disease r elated outcomes in 8 health domains, including vitality, physical 
functioning, bodily pain, general health perceptions, physical role functioning, emotional role 
functioning, social functioning, and mental health. The score (ranging from 0 to 100) is prese nted 
in two components: a mental composite scale (MCS) and physical composite scale (PCS).  The 

EDP1815 -[ADDRESS_690384] been 
shown to correlate with those of the 36 -Item Short Form Heal th Survey (SF -36) (Ware J, 1996) . 
 
8.10. Hospi[INVESTIGATOR_421423] (HADS) is a PRO instrument used to measure anxiety 
and depression over the past week.  It is comprised of 7 questio ns for anxiety and 7 questions for 
depression and each are scored using a 4 -point Likert scale (e.g., 0 -3). Scores for each domain 
therefore range from 0 -21, where 8 -10 is mild, 11 -14 is moderate and 15 -21 is severe anxiety or 
depression  (Snaith, 2003) . 
 
8.11. Atopic Dermatitis Control Tool  
The Atopic Dermatitis Control Tool (ADCT) is a [ADDRESS_690385] change 
of disease activity in a person over time.  There are six main areas that assess the multi -dimensiona l 
aspects of disease control over the course of a week, scored between 0 -4, with a minimum score 
of 0 and a maximum score of 24.  A higher score indicates lower AD control.  A change of 5 points 
is the threshold for meaningful within person change, where a  decrease of 5 or more points 
indicates clinically relevant improvement of AD control and an increase of 5 or more points 
indicates a clinically relevant worsening of AD control (Pariser, 2020) . 
 
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 56 of 114 
9. SAFETY ASSESSMENTS  
 
The adverse event (AE) definitions and reporting procedures provided in this protocol comply with 
all applicable regulations and International Conference on Harmonization (ICH) guidelines. The 
Investigator will carefully monitor each subject throughout the  study for possible adverse events.  
 
9.1. Adverse Events  
An adverse event (AE) is any unfavorable and unintended sign (including a clinically significant 
abnormal laboratory finding, for example), symptom, or disease temporally associated with a 
study, use of a drug product or device whether or not considered related to the drug product or 
device.  
 
Signs or symptoms of the condition/disease for which the IMP is being studied should be recorded 
as AEs only if their nature changes considerably or their frequency  or intensity increases in a 
clinically significant manner as compared to the clinical profile known to the investigator from the 
participant’s history or from Day 1.  
 
9.1.1.  Adverse Events of Special Interest  
There are no prespecified AEs of special interest (AE SI) for this study.  
 
9.2. Adverse Drug Reactions  
Adverse drug reactions (ADR) (also known as suspected unexpected adverse drug reactions or 
S[LOCATION_003]Rs) are all noxious and unintended responses to a medicinal product related to any dose. 
The phrase “responses to a m edicinal product” means that a causal relationship between a 
medicinal product and an adverse event is at least a reasonable possibility, i.e., the relationship 
cannot be ruled out. Therefore, a subset of AEs can be classified as suspected ADRs or S[LOCATION_003]Rs, 
if there is a causal relationship to the medicinal product.  
 
9.3. Serious Adverse Events  
A serious adverse event (SAE) is defined as an adverse event that meets any of the following 
criteria:  
 
• Results in death.  
 
• Is life threatening; that is, poses an immediate risk of death as the event occurred.  
− This serious criterion applies even if the participant, in the view of the Investigator or 
Sponsor, is at immediate risk of death from the AE as it occurs.  It does not apply if an AE 
hypothetically might have  caused death if it were more severe.  
 
• Requires inpatient hospi[INVESTIGATOR_1081].  
− A participant admitted to a hospi[INVESTIGATOR_307], even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospi[INVESTIGATOR_18543]. An emergency room visit that results in 
admission to the hospi[INVESTIGATOR_58912]. 
However, emergency room visits that do not result in admission to the hospi[INVESTIGATOR_531762], instead, should be evaluated for 1 of the other criteria in the 
definition of serious (e.g.,  life threatening adverse experience, important medical event).  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 57 of 114 
− Hospi[INVESTIGATOR_58913] (e.g.,  preplanned 
surgery or elective surgery for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner) do not qualify for reporting.  
◦ For example, if a participant has a condition recorded on his/her medical history and 
later has a preplanned surgery for this condition, it is not appropriate to record the 
surgery or hospi[INVESTIGATOR_18256], since there is no AE upon which to assess the 
serious criteria.  
◦ Please note that, if the pre -existing condition has worsened or manife sted in an unusual 
or uncharacteristic manner, this would then qualify as an AE and, if necessary, the 
seriousness of the event would need to be determined.  
 
• Results in persistent or significant disability or incapacity.  
− This serious criterion applies if t he “disability” caused by [CONTACT_243077] a 
substantial disruption of the participant’s ability to carry out normal life functions.  
 
• Results in a congenital anomaly or birth defect in the offspring of the participant (whether the 
participant is male or female).  
 
• Is an important medical event that, based upon appropriate medical judgment, may jeopardize 
the participant and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious.  
− Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias that do not result in inpatient 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
 
9.4. Reporting and Record ing AEs  
The Investigator will carefully monitor each participant throughout the study for possible AEs.  In 
order to ensure complete safety data collection, all AEs occurring during the study (i.e.,  after the 
signing of the Informed Consent form), including the pr e-treatment period required by [CONTACT_12695], must be reported in the CRF even if no IMP was taken but specific study procedures 
were conducted. This includes all AEs not present prior to the initial visit and all AEs that recurred 
or worsened after the ini tial visit.   
 
All AEs will be collected and reported in the electronic data capture (EDC) system and compi[INVESTIGATOR_531763]. The Medical Monitor shall promptly 
review all information relevant to the safety of the investigational product, including all serious 
adverse events (SAEs). Special attention will be paid to those that result in permanent 
discontinuation of the investigational product being studied, whether serious or non -serious.  
  
If the inve stigator learns of any SAE, including a death, at any time after a participant has been 
discharged from the study, and he/she considers the event to be reasonably related to the IMP or 
study participation, the investigator must promptly notify the sponsor (or designee).  
 
Serious AEs that occur more than [ADDRESS_690386] been hospi[INVESTIGATOR_057], had any accidents, used any new 
medications, changed concomitant medication re gimens (prescription or OTC medications), 
noticed any changes in bowel habits or had unplanned visits to their general practitioner since the 
last visit.  
 
In addition to participant observations, AEs identified from any study data (e.g., laboratory values , 
physical examination findings, ECG changes) or identified from review of other documents (e.g., 
participant diaries) that are relevant to participant safety will be documented on the AE page in the 
CRF.  
 
If the participants reports an adverse event, the following will be recorded in the source and on the 
eCRF:  
1. Description of the event  
2. Date and time of onset and resolution (duration)  
3. Record grading as per appropriate toxicity scale  
4. Seriousness (does the event meet the above definition for an SAE)  
5. Causal ity, relation to investigational product  
6. Action taken regarding investigational product  
7. Outcome  
8. If any Concomitant Medications were given  
9. Whether the AE resulted in participant withdrawal from the study  
10. Investigator -specified assessment if the AE is related to a recent/current COVID 
infection  
11. If a COVID positive PCR test received within the last 14 days  
 
Signs or symptoms of a participant’s atopic dermatitis should be recorded as AEs only if their 
nature changes considerably or their frequency or inte nsity increases in a clinically significant 
manner as compared to the clinical profile known to the Investigator from the participant’s history.   
 
9.4.2.  Assessment of Severity  
The severity, or intensity, of an AE refers to the extent to which an AE affects the participant’s 
daily activities or their health. The intensity of the AE will be rated in accordance with the CTCAE 
Version 5.0.  Adverse events related to temperature and abnormal laboratory results that are not 
found in the CTCAE Version 5.0 will be rated  in accordance with the FDA Guidance for Industry 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials  [Appendix 14.5 Toxicity Grading Scale ]. 
 
Changes in the severity of an AE should be documented to allow an assessment of the duration of 
the event at each level of intensity to be performed. Adverse events characterized as intermittent 
do not require documentation of ons et and duration of each epi[INVESTIGATOR_1865].  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 59 of 114 
9.4.3.  Assessment of Causality  
The investigator’s assessment of an AE’s relationship to IMP is part of the documentation process. 
Regardless of the investigator's assessment of an AE's relationship to IMP, the AE must be 
reported .  
 
The relationship or association of the IMP in causing or contributing to the AE will be 
characterized using the following classification and criteria:  
 
Unrelated :   There is no association between the IMP and the reported events.  
 
Possible : Treatment with the IMP may have caused or contributed to the AE, i.e., the 
event follows a reasonable temporal sequence from the time of drug 
administration or follows a known response pattern to the IMP but could also 
have been produced by [CONTACT_531791].  
 
Probable : A reasonable temporal sequence of the event with drug administration exists 
and, based upon the known pharmacological action of the drug, known or 
previously reported adverse reactions to the drug or class of drugs, or judgment 
based on the inv estigator’s clinical experience, the association of the event with 
the IMP seems likely. The event disappears or decreases on cessation or 
reduction of the dose of IMP.  
 
Definite : A definite causal relationship exists between drug administration and the AE, 
and other conditions (concurrent illness, progression/expression of disease 
state, or concurrent medication reaction) do not appear to explain the event. The 
event reappears or worsens if the IMP is re -administered.  
 
9.4.4.  Description of Adverse Events  
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF and 
source documents should be consistent. Any discrepanc ies between the participant’s own words 
on his/her own records (e.g.,  diary card) and the corresponding medical terminology should be 
clarified in the source documentation.  
 
Details for completion of the Adverse Event eCRF are described in the eCRF Complet ion 
Guidelines.  
 
[IP_ADDRESS].  Rule for Repetition of an AE  
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:  
 
• The outcome date of the first AE that is not related to the natural course of the disease being 
the same as th e start date of the repeated AE, and the outcome of “worsening”.  
 
• The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 61 of 114 
9.7. Overdose  
Excessive dosing (greater than 4 capsules within 24 hours) should be recorded in the CRF. 
Participants will be instructed to contact [CONTACT_531792] a suspected overdose.  
 
Any overdose must be promptly reported to  via the Special Situations 
Form. Overdose itself is not to be  reported as an AE. However, any AEs or SAEs associated with 
the overdose are to be reported on relevant AE/SAE sections in the eCRF and on the Paper SAE 
Form provided to  (Section  9.5 Reporting Serious Adverse Events ).  
 
In the event of a symptomatic overdose, the Investigator should:  
 
1. Manage the patient symptomatically with supportive care.  
2. Contact [CONTACT_531793].  
3. Document the quantity of the excess dose in the eCRF.  
4. Document the overdose symptoms and their duration in the eCRF.  
 
Doses of EDP1815 capsules that have previously been administered include a dose of 8.0 x 1011 
cells taken once daily for 16 week s, and 1.28 x 1012 cells taken once daily for 8 weeks. There are 
no specific expected adverse events expected in an overdose, but the participant should be closely 
and carefully monitored. There is no specific treatment or antidote, but supportive clinical  care 
should be provided as dictated by [CONTACT_2299]’s clinical status.  
 
Decisions regarding dose interruptions or modifications will be made by [CONTACT_531794] t. 
 
9.8. Safety Signal Detection  
Selected data from this study will be reviewed periodically in a blinded fashion to detect as early 
as possible any safety concern(s) related to the IMP so that Investigators, clinical study 
participants, regulatory authorities, and IRBs/IECs will be informed appropriately and as early as 
possible.  
 
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs.  DM will perform ongoing SAE reconciliations in collaboration wi th the PV 
representative.  
 
As appropriate for the stage of development and accumulated experience with the IMP, medically 
qualified personnel at the Sponsor may identify additional safety measures (e.g.,  AEs, vital signs, 
laboratory or ECG results) for whi ch data will be periodically reviewed during the course of the 
study.  
 
9.9. Study Halting Criteria  
The study will be halted if any of the following occur:  
• One fatal SAE considered definitely, probably, or possibly related to the investigational 
product.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 62 of 114 
• Two or more participants with a non -fatal SAE considered definitely, probably, or possibly 
related to the investigational product.  
 
• Three or more participants with grade [ADDRESS_690387].  
 
• Any participant develops a documented Prevotella histicola  infection in a sterile space 
confirmed by [CONTACT_531795]/or qPCR.  
 
9.10. Laboratory Measurements  
Standard laboratory analyses to understand safety and tolerability include the f ollowing 
measurements:  
 
Hematology  Biochemistry  Urinalysis  
Complete Blood Count 
with differentials:  Alanine Aminotransferase 
(ALT)  Bilirubin  
Hemoglobin  Aspartate Aminotransferase 
(AST)  Blood  
Hematocrit  Creatinine  Glucose  
Platelet count  C-Reactive Protein (CRP)  Ketones  
Red blood count (with 
percent reticulocytes)  Gamma -glutamyl 
transpeptidase (GGT)  Nitrites  
Mean Corpuscular 
Hemoglobin (MCH)  Potassium  pH 
Mean Corpuscular 
Hemoglobin 
Concentration (MCHC)  Sodium  Protein  
Mean Corpuscular 
Volume (MCV)  Total Bilirubin  Specific 
Gravity  
White blood cell count:  Urea   
Basophils    
Eosinophils    
Lymphocytes    
Monocytes    
Neutrophils    
 
A serum pregnancy test will be performed on women of childbearing potential (WOCBP) at the 
Screening Visit.  Urine pregnancy testing will be conducted on Day 1 and then monthly thereafter.   
 
Additional testing may be ordered if needed, to further assess a n adverse event (AE), or if there is 
any suspi[INVESTIGATOR_40958] a subject may be pregnant, throughout the course of the study.  
 
Only abnormal laboratory test results (hematology, clinical biochemistry, or urinalysis) or other 
safety assessments (e.g., ECGs, vital sign measurements), which are clinically significant in the 
medical and scientific judgment of the investigator, are to be recorded as AEs or SAEs.  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 63 of 114 
A central laboratory (or specialized central laboratories) will be used for all laboratory analyses. 
Details of sample collection and handling procedures will be provided in the specific laboratory 
manual.  
 
9.10.1.  Review of Laborator y Measurements  
The Investigator must review the laboratory reports, document this review, and record any 
clinically relevant changes occurring during the study. If the laboratory reports are not transferred 
electronically, the values must be filed with the  source information (including reference ranges). 
In most cases, clinically significant abnormal laboratory findings are those that are not associated 
with the underlying disease, unless judged by [CONTACT_531796]'s condition.  
 
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study or within [ADDRESS_690388] dose of IMP should be repeated until the values return 
to normal or baseline value or a re no longer considered clinically significant by [CONTACT_114999]. If such values do not return to normal/baseline within a time judged reasonable 
by [CONTACT_737], the etiology should be identified, and the Sponsor notified.  
 
All pr otocol -required laboratory assessments, as defined in this section, must be conducted in 
accordance with the laboratory manual and the SOA. Screening laboratory results will be used to 
confirm eligibility at Day 1.  If laboratory values from non -protocol s pecified laboratory 
assessments performed at the institution’s local laboratory require a change in participant 
management or are considered clinically significant by [CONTACT_737] (e.g., SAE or AE or dose 
modification), then the results must be recorde d on the Adverse Events eCRF.  
 
9.10.2.  Blood Volumes  
The planned maximum amount of blood collected from each participant over the duration of the 
study, including any extra assessments that may be required, will not exceed 145 mL. Repeat or 
unscheduled samples ma y be taken for safety reasons or for technical issues with the samples. The 
planned maximum amount of blood collected from each participant at a single visit will not exceed 
25 mL, and the planned maximum amount of blood collected from each participant ove r 30 days 
will not exceed 48 mL.  
 
9.11. Biomarkers  
 
9.11.1.  Genetic Testing  
Optional blood samples may be collected at Day 1 for genetic testing, such as human leukocyte 
antigen (HLA) typi[INVESTIGATOR_200267] (WGS). The data will be used to correlate 
with the clinical outcomes in order to identify patient group(s) who ma y benefit the most from 
EDP1815 treatment.  Only genetic variants that cause different responses to EDP1815 will be 
assessed.  This sample will be stored for a maximum of 10 years and will be destroyed if not used 
within this time. This is an optional coll ection sample where local regulations and IRBs/IECs 
allow.  This sample will only be collected on those participants who consent to participate in this 
optional  blood collection for genetic testing.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 64 of 114 
9.11.2.  Immune Protein Markers  
Immunoglobulin E (IgE) are antibo dies produced by [CONTACT_531797], particularly with the phenotype known as ‘extrinsic’ AD (Renert -Yuval, 2021) . 
IgE is a recognized biomarker of disease severity in AD and is regularl y measured in clinical 
practice. It is being measured in participants to see if treatment response can be predicted by [CONTACT_2006] 
[ADDRESS_690389] immune response as well as those related to the disease pathology.   
 
9.11.4.  Microbiome Sample  
A fecal sample will be collected within 7 days of Day 1 to enable microbiome sampling. The 
purpose of this sample will be t o perform analysis of stool bacterial DNA, to see if there is a 
correlation between background microbial content in the large intestine, and response to treatment 
with EDP1815. Participants will be provided with a fecal collection kit and instructions at t he 
Screening Visit with instructions to bring the sample in at their Day 1 visit.   Any participant that 
enrolls in the study under Protocol Version 5.0 is not required to provide a fecal sample.  
  
9.12. Other Safety Measurements  
 
9.12.1.  Vital Signs, Height and Weight  
Vital signs will be obtained after the participant has been in a seated position for approximately 5 
minutes. Vital signs, including systolic and diastolic blood pressure, pulse rate (radial 
artery)/minute, respi[INVESTIGATOR_697]/minute, and temperature.  Height will be measured and recorded at 
the Screening Visit only. Weight will be assessed at specified visits (without shoes and street 
clothing).  Body mass index will be calculated from the height and weight.  Investigators should 
pay special attention to clini cal signs related to previous serious illness.  
  
9.12.2.  Physical Examination  
A physical examination (PE) will be performed and recorded in source at specified visits.  Only 
abnormal, clinically significant findings will be recorded as AEs on the eCRF.  
 
The following systems will be examined when a full PE is indicated: general appearance, 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, musculoskeletal, central nervous system, lymph 
nodes and skin.  
 
The following systems will be examined when a brief PE i s indicated: general appearance, 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal and skin.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 65 of 114 
9.12.3.  12-Lead Electrocardiogram  
A single 12 -lead electrocardiogram (ECG) will be obtained at specified visits using an ECG 
machine that automatically calculates heart rate and measures PR, RR, QRS, and QT interval.  
QTcF (Fridericia) intervals  will be auto derived  and populated in the case report form (CRF) .   
 
A single ECG tracing is to be obtained on the day of the visit after the participant has been in a 
lying position f or approximately 5 minutes.  If in the opi[INVESTIGATOR_689], there appear to 
be clinically significant findings, it should be repeated.  If the repeated tracing also appears 
clinically significant, the Investigator should report the abnormality as a n AE and consult with the 
Medical Monitor to decide whether the participant should continue treatment in the study.  
 
9.13. Non-Safety Measurements  
 
9.13.1.  Digital Photography  
Digital photographs should be taken of the upper and lower body (upper & lower anterior and 
upper & lower posterior) as half body shots at Day 1.  Additional photographs of up to six specific 
body areas, i.e., limbs, trunks, and back, will also be taken.  The same locations photographed at 
Day 1 should be followed through the study for each participant.    
 
Procedural details for digital photography will be provided to the sites.  
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
CONFIDENTIAL   Page 66 of 114 
10. STUDY MANAGEMENT AND ADMINISTRATION  
 
10.1. Adherence to protocol  
A deviation from the protocol is an unintended or unanticipated departure from the procedures or 
processes approved by [CONTACT_1035]/IEC and agreed to by [CONTACT_737]. A 
significant deviation occurs when there is non -adherence to the protocol or to local regu lations or 
ICH GCP guidelines that may or may not result in a significant, additional risk to the participant 
or impacts the integrity of study data.  
 
The Investigator should not deviate from the protocol. However, the Investigator may implement 
a deviatio n from, or a change of, the protocol to eliminate an immediate hazard/safety risk to study 
participants without prior IRB/IEC approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should be submitted to the IRB/IEC for review and approval, to the Sponsor for agreement, and to 
the regulatory authorities, where required.  The deviation should be well documented in the 
participant’s source documentation.  
 
In order t o keep deviations from the protocol to a minimum, the Investigator and relevant site 
personnel will be trained in all aspects of study conduct by [CONTACT_46887]. 
This training will occur either as part of the Investigator’s Meeting o r Site Initiation Visit (SIV). 
Ongoing training may also be performed throughout the study during routine site monitoring 
activities.  
 
10.2. Monitoring  
Monitoring of the study will be delegated by [CONTACT_531798] (CRO) handling project, data and site management.  will monitor the study to 
meet their monitoring Standard Operating Procedures (SOPs), the monitoring plan, ICH -GCP 
guideline, and applicable regulatory requirements, and to ensure that study initiation, condu ct, and 
closure are adequate.  
 
The Investigator and site staff are expected to cooperate with the Sponsor and and to be 
available during the monitoring visits (whether onsite or remote, if needed) to answer questions 
sufficiently and to provide any mi ssing information. The Investigator(s)/institution(s) will permit 
direct, secure access to source data/documents for study -related monitoring, audits, IRB/IEC 
review, and regulatory inspection(s).  
 
The Investigator will allow the Sponsor or  to periodically review all eCRFs and 
corresponding source documents (e.g.,  hospi[INVESTIGATOR_58921]). 
Monitoring visits (whether onsite or remote, if needed) will provide the Sponsor and with the 
opportunity to evaluate t he progress of the study, verify the accuracy and completeness of CRFs, 
ensure that all protocol requirements, applicable authorities regulations, and investigator’s 
obligations are being fulfilled, and resolve any inconsistencies in the study records.  
 
10.2.1.  Definition of Source Data  
Source documents are original records in which raw data are first recorded. These may include 
hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, x -rays, laboratory results, printouts, 

EDP1815 -[ADDRESS_690390] be accurate, clear, unambiguous, permanent, and capa ble of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should not be obscured by [CONTACT_18411] (such 
as removable self -stick notes). Photocopi[INVESTIGATOR_13265]/or p rintouts of CRFs are not considered acceptable 
source documents.  
 
The following data will be considered as electronic source and therefore, will not be recorded 
directly into the EDC an d will not appear in a separate source document as defined above. 
However, paper source documents may be utilized for collection of PROs and COAs listed below 
should there be an unforeseeable circumstance (such as a power outage) and the electronic source 
is unavailable.   Any information about a participant that is colle cted during this study will remain 
secured and confidential and will be handled per applicable regulations (i.e., data collected via 
mobile applications).  
 
• Participant Electronic Diary (eDiary) including IMP, emollient and rescue therapy 
usage and PP -NRS a nd SD -NRS daily questionnaire. A paper diary will be utilized 
between the Screening and Day [ADDRESS_690391] participant information on emollient 
usage, participant’s worst itch and participant’s sleep.  
 
• Patient Reported Outcome Measurements (PROs), inc luding POEM, DLQI, ADCT, 
SF-12, and HADS.  
 
• Clinician Outcome Assessments (COAs) including EASI, BSA, vIGA, and SCORAD.  
 
Source documents that are computer generated and stored electronically must be printed for review 
by [CONTACT_2037] (e.g.,  ECG reports, lab oratory reports). Once printed, these copi[INVESTIGATOR_531764] a permanent part of the participant’s source documents. 
The Investigator will facilitate the process for enabling the monitor to compare the content of t he 
printout and the data stored in the computer to ensure all data are consistent.  
 
10.2.2.  Source Data Verification  
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to  being accurate, complete, and verifiable from 
source documents (e.g.,  participant files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the eCRF should be supported by [CONTACT_58992], unless o therwise specified in Section 10.2.1  Definition of Source Documents . 
 
10.3. Data Management  
 
10.3.1.  Data Quality Assurance  
This study will be conducted according to ICH E6(R2) risk and quality processes described in the 
applicable procedural documents.  The quality management approach to be implemented in this 

EDP1815 -[ADDRESS_690392] 
be accompanied by a reason for the change. Corrections made after the Investigator’s review and 
approval (by [CONTACT_3553] a password/electronic signature) will be reapproved by [CONTACT_737]. 
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
CRF.  
 
Detailed instructions will be provided in the CRF Completion Guidelines.  
 
10.3.3.  Data Entry and Reconciliation  
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database that is validated and compliant with US Title [ADDRESS_690393] copy audits, 
discrepancy reviews, and investigat or comment information.  
 
After all data reviews and query resolutions are complete, the SAP is approved and signed, and 
any summary/analysis populations are approved, the database will be locked.  
 
10.3.4.  Participant Screening & Enrollment Log/Participant Identif ication Code List  
The participant’s Screening and Enrollment will be recorded in the Participant Screening and 
Enrollment Log.  
 
The Investigator will keep a Participant Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each participant.  
 
The participant’s consent and enrollment in the study must be recorded in the participant’s medical 
record. These data should identify the study and document the dates of the participant’s 
participation.  
 

EDP1815 -[ADDRESS_690394] to quality or quantity.  
 
If the study is prematurely terminated or suspended, the Sponsor (or its representative) will inform 
the Investigators/institutions a nd the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
terminat ion or suspension by [CONTACT_12942]/institution, as specified by [CONTACT_12926](s). In addition, arrangements will be made for the return of all 
unused IMP/investigational device and other material in accordance w ith the Sponsor’s procedures 
for the study.  
 
10.5. Archiving and Data Retention  
The Investigator will maintain adequate records for the study, including CRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition record s, safety 
reports, information regarding participants who discontinued, and other pertinent data.  
 
All essential documents are to be retained by [CONTACT_31201] [ADDRESS_690395] elapsed since the 
formal discontinuation of clinical development of the IMP/investigational device. These 
documents should be retained for a longe r period, however, if required by [CONTACT_3605](s) or by [CONTACT_16268] (EMEA, 2002 Jul) . 
 
The Investigator will contact [CONTACT_531799]. The Investigator will 
also notify the Sponsor in writing should he/she relocate or move the study --related files to a 
location other than that specified in the Sponsor’s Trial Master File (TMF).  
 
10.6. Audit and Inspection  
The Investigator will permit study --related audits mandated by [CONTACT_1034], after reasonable 
notice, and inspections by [CONTACT_58995].  
 
The main purposes of an audit or inspection are to  confirm that the rights and well -being of the 
participants enrolled have been protected, that enrolled participants (i.e.,  signing consent and 
undergoing study procedures) are appropriate for the study, and that all data relevant for the 
evaluation of the  IMP/investigational device have been processed and reported in compliance with 
the planned arrangements, the protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and 
applicable regulatory requirements.  
 
The Investigator will provide direct access to  all study documents, source records, and source data. 
If an inspection by a regulatory authority is announced, the investigator will immediately inform 
the Sponsor (or designee).  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
CONFIDENTIAL   Page 70 of 114 
 
10.7. Good Clinical Practice  
Noncompliance with the protocol, ICH -GCP, or local r egulatory requirements by [CONTACT_737], 
institution, institution staff, or designees of the Sponsor will lead to prompt action by [CONTACT_531800]. Continued noncompliance may result in the termination of the site’s 
involvement in the s tudy.  
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 71 of 114 
11. STATISTICS  
 
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan.   
 
11.1. Definition of Analysis Sets  
The following analysis sets will be used in the statistical analyses.  
 
11.1.1.  Participant Analysis Sets  
Enrolled set : The enrolled set will consist of all participants who sign the ICF.  
 
Full analysis set : The FAS set will consist of all participants who were randomized to treatment. 
All analyses using the FAS will group participant s according to randomized treatment.  
 
Safety analysis set : The SAS will consist of all participants who received any IMP. All analyses 
using the safety set will group participants according to treatment received.  
 
11.1.2.  Defined Data Point Sets  
The following eff icacy data point sets (EDPS) and safety data point sets (SDPS) are defined:  
 
EDPS1 :  Consists of all data collected at a scheduled timepoint that is at least 28 days after use of 
topi[INVESTIGATOR_531745] . Data collected less than 28 days after  such use or data missing 
due to withdrawal from the study for reasons considered related to study medication will be 
replaced as follows:  
• Continuous endpoints: value will be imputed with the last off -rescue observation carried 
forward (off -rescue is defin ed as data collected at least 28 days after use of rescue medication)  
• Responder endpoints: value will be imputed as non -response.  
• Count endpoints: N/A (No count endpoint will use this DPS).  
Data missing for other reasons, including early withdrawal from the study due to reasons not 
considered related to study medication will not be replaced and will be considered as missing.  
 
EDPS2 : Consists of all data collected at a scheduled timepoint that is at least 28 days after use of 
topi[INVESTIGATOR_531765] . Data collected less than 28 days after such use will be 
considered as missing and excluded from the analysis. Data missing due to withdrawal from the 
study for reasons considered related to study medication will be imputed as per D PS1. Data 
missing for other reasons will not be replaced.  
 
EDPS3 : Consists of EASI -[ADDRESS_690396] udy medication will not be replaced and will be considered as 
missing.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 72 of 114 
EDPS4 : Consists of EASI -[ADDRESS_690397] 28 days 
after use of topi[INVESTIGATOR_531745] . Data collected less than 28 days afte r such use 
will be replaced as per DPS1.  Data missing due to other reasons including early withdrawal from 
the study for any reason will not be replaced and be considered as missing.  
 
EDPS5 : Is a subset of DPS1 for the EASI -50 response data only, excludi ng any data collected or 
imputed after the use of a prohibited medication or the unblinding of a participant (whichever 
occurs first) and excluding all data from subjects who take <75% of expected doses or whose 
compliance with emollient use was <75% or di d not complete the 12 -week treatment period.  
 
EDPS6 : Consists of data collected in the absence of topi[INVESTIGATOR_531766] 1  for the responder endpoints relating to EASI, vIGA and PP -NRS . Data collected 
after such use or missing due to withdrawal from the study for reasons considered related to study 
medication will be imputed as non -response.  
 
Response s missing for other reaso ns, including early withdrawal from the study due to reasons not 
considered related to study medication will not be replaced and will be considered as missing.  
 
EDPS7 : Contains all data collected as part of a count endpoint. A treatment policy strategy wil l be 
used for all intercurrent events other than discontinuation from the study which will use a while 
on treatment strategy (i.e., the collection period will be ended at the time of study discontinuation).  
 
SDPS1 : Consists of all observed data collected a t a scheduled visit.  
 
SDPS2 : Consists of all observed data collected, including data from scheduled and unscheduled 
visits.  
 
The FAS with EDPS1 are used to estimate the primary estimand and all secondary and exploratory 
estimands (excluding those relating  to count endpoints).  
 
The FAS with EDPS2 -EDPS6 will be used to estimate supplementary estimands for the primary 
endpoint.  The FAS with EDPS2  and EDPS6  will be used to estimate supplementary estimands for 
selected secondary estimands.  
 
The FAS with EDPS7 are used to estimate the secondary estimands relating to count endpoints.  
 
The SAS and SDPS1 are used to present safety data assigned to specific scheduled visits.  
 
The SAS and SDPS2 are used to present all other safety data, including adverse events.  
 
Note that all subjects who withdraw from the study prematurely will be evaluated prior to database 
lock and unblinding will have their reason for withdrawal evaluated as being related or non -related 
to study medication.   
 
11.2. General Statistical Cons iderations  
Statistical analysis will be performed using SAS software Version  9.[ADDRESS_690398] deviation, median, minimum 
value, and maximum value. Categorical variables will be summarized usin g frequency counts and 
percentages. Daily time to event response endpoints will be summarized using the Kaplan -Meier 
estimates of the proportion of responders in each study week together with the estimated median 
and quartiles for time to response.  
 
Descri ptive statistics will also be used extensively in figures to visualize the data.  These include 
but are not limited to mean (SE) or LS Mean (95% CI) plots against time, waterfall plots for 
individual changes at a specific time point, vertical bar plots sho wing percentages of responders 
and Kaplan -Meier plots.  
Data will be listed in data listings.  
 
Baseline will be defined as the last non -missing data available prior to the first dose of IMP. Data 
on Day [ADDRESS_690399] dose of IMP.  
 
The subgroup of participants with IGA=3 at Day 1 will be used to perform subgroup analyses on 
the primary estimand. Data for the subgroups defined by [CONTACT_78442]=2 and IGA=4 at baseline will be 
summarized but no analysis done as the sample sizes are not expected to be large enough for 
meaningful comparisons to be made.  
 
The focus of this study is on model estimation of treatment effects and as such no adjustments will 
be made for multiple testing in this study.  
 
Two sets of tables, figures and listing s will be provided, one for the combined analysis of Cohorts 
1-3 and one for the analysis of Cohort 4.  
 
Cohort 1 -3 Analysis  
The placebo participants from Cohorts 1, 2 and 3 will be pooled and compared to the following 
active treatment groups:  
• EDP1815 1.6x1011 QD (Cohort 1)  
• EDP1815 6.4x1011 QD (Cohort 2)  
• EDP1815 3.2x1011 BID (Cohort 3)  
• EDP1815 6.4x1011 Daily (Cohorts 2 and 3)  
• All EDP1815 (Cohorts 1, 2 and 3)  
 
For the primary analysis, the first three comparisons using the individual cohorts only  will be 
considered as primary with the pooled active comparisons considered as secondary.  
 
The following comparisons between active treatment groups will also be performed but will be 
considered as exploratory in nature:  
• EDP1815 6.4x1011 QD (Cohort 2) vs EDP1815 3.2x1011 BID (Cohort 3)  
• EDP1815 1.6x1011 QD (Cohort 1) vs EDP1815 6.4x1011 QD (Cohort 2)  
 
Cohort 4 Analysis:  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 74 of 114 
The analyses for Cohort 4 will compare EDP1815 8.0x1010 to a combined control group including 
the Cohort 4 placebo participants (approximat ely 35) and set of matched placebo participants from 
Cohorts 1 -3 (approximately 35). This will provide a total of approximately 70 placebo participants, 
resulting in a 1:[ADDRESS_690400] estimates  (Viele, 2014) . A 
propensity -score based matching algorithm will be used to select patients from the Cohort 1 -3 
Placebo group in to order balance key baseline characteristics  (Austin, 2011) . Matching will be 
performed based on propensity scores derived from baseline characteristics such as IGA, EASI 
score, BSA, gender, and country. Full details of the matching algorithm are provided in the SAP.  
 
Summary tables for Cohort 4 will include a column for the Cohort 4 Only Placebo group in 
addition to columns for the Cohort 4 Matched Placebo group as well as the EDP1815 8.0x1010 
group.  
 
Analysis tables and figures will include onl y the Cohort 4 Matched Placebo group and the 
EDP1815 8.0x1010 group and all primary and secondary comparisons will be between these two 
groups.  
 
As an exploratory analysis, analyses may be repeated including the EDP1815 1.6x1011 QD (Cohort 
1) treatment gro up in the statistical models for Cohort 4. For these analyses the comparison of 
interest will be between the two active EDP1815 treatment groups (Cohort 1 vs Cohort 4).  
  
11.3. Estimands and Intercurrent Events  
 
11.3.1.  Primary Estimand and Supplementary Estimands of the Primary Objective  
The primary estimand and the supplementary estimands for the primary objective will consider the 
effect of each individual EDP1815 cohort compared to the relevant placebo group (Cohort 1 -3 
Pooled Placebo for comparisons t o C1 -3 EDP1815 groups; and Cohort 4 Matched Placebo for 
comparison to the Cohort 4 EDP1815 group) on the percentage of participants achieving EASI -[ADDRESS_690401] will be the odds ratio between each active EDP181 5 
treatment group and the relevant placebo group.  
 
The FAS participant analysis set will be used.  
 
Strategies for intercurrent events will be accounted for in the following manner using the relevant 
EDPS as follows:  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 80 of 114 
Actual and predicted probabilities of EASI -50 at Week 16 for each treatment group will be plotted.   
 
11.4.2.  Analysis of Supplementary Estimands on the Primary Objective  
The four supplementary estimands defined for the primary objective will be analyzed in the same 
manner as the primary estimand.  
 
For the potential covariates of body mass index, gender, race and region: thos e covariates found 
to be significant in the primary analysis will be included in all models regardless of significance 
in order to ensure comparability of the models.  
 
11.4.3.  Cohort 4 Sensitivity Analysis of the Primary Estimand  
A Bayesian dynamic borrowing metho d using a commensurate prior will be used for the placebo 
comparator in the primary analysis model, utilizing all Cohort 4 data and Cohort 1 -3 placebo data  
(Hobbs, Carlin, Mandrekar, & Sargent, 2011) . In contrast to the primary analysis method, this 
sensitivity analysis will borrow information from the Cohort 1 -3 placebo patients dependent on 
the similarity in outcomes between the Cohort 4 and Cohorts 1 -3 placebo groups further sensitivity 
analyses for  the primary and secondary endpoints may also be performed on the Cohort 4 data 
either using the same dynamic borrowing methodology or using the Cohort 4 only placebo group 
as the comparator. Full details are provided in the SAP.  
 
11.4.4.  Analysis of Secondary Es timands  
Continuous secondary estimands will be analyzed using a mixed model for repeated measures 
(MMRM) with parameters for treatment group, visit, baseline IGA score and relevant baseline 
score and the interaction for treatment*visit.   
 
For the potentia l covariates of body mass index, gender, race and region: those covariates found 
to be significant in the primary analysis will be included in all models regardless of significance 
in order to ensure comparability of the models.  
 
Least squares mean estimat es and their 95% confidence intervals (CI) will be presented for the 
endpoint value at each visit. Treatment differences between each EDP1815 group and the pooled 
placebo group will be estimated using LS mean differences, 95% CI and p -values. Pairwise 
treatment differences between EDP1815 groups will be estimated with LS mean differences and 
95% CI.  
 
Least square mean (95% CI) estimates will be plotted against visit.  Least square mean (95% CI) 
treatment differences between each EDP1815 treatment group and the pooled placebo group will 
also be plotted against visit.  
 
Response estimands will be analyzed with a generalized linear mixed effects model with a logit 
link function. Treatment, visit, baseline IGA and the appropriate baseline questionnaire score will  
be included as parameters together with the treatment*visit interaction.  Odds ratios with 95% CIs 
and p -values for each EDP1815 group compared to the relevant pooled placebo group at each visit 
will be presented.  Odds ratios and 95% CIs will be presente d for any comparisons between two 
EDP1815 treatment groups.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 81 of 114 
In the event that there are no responders in one of the treatment groups at a visit, data from that 
visit will be excluded from the model and only summary statistics will be produced showing the 
number and percentage of responders at that visit.  
 
Count estimands will be analyzed with a Poisson regression model fitted with treatment and 
baseline IGA as covariates. An offset of log (days in study) will also be included in the model to 
account for an y data from participants who withdrew early from the study. If the distribution of 
the count data suggests over -dispersion and/or zero inflation, then other models including the 
negative binomial or zero -inflated Poisson model may be considered.  
 
Model est imated event rates and their 95% confidence intervals will be presented for each 
treatment group. Rate ratios with 95% CIs and p -values for each EDP1815 group compared to the 
relevant pooled placebo group at each visit will be presented.  Rate ratios and 9 5% CIs will be 
presented for any comparisons between two EDP1815 treatment groups.  
 
11.4.5.  Analysis of Exploratory Estimands  
Exploratory endpoints will be summarized only. No inferential analysis is planned.  
 
For the daily PP -NRS and SD -NRS endpoints which are evaluated daily only graphical summaries 
will be presented.  
 
For the time to first response endpoints for the PP -NRS and SD -NRS scores, participants who have 
not met the response definition before the We ek 16 visit will be censored at the Week 16 visit, or 
at the time of withdrawal from the study for those who withdrew before Week 16.  
 
For the time to sustained response endpoints for the PP -NRS and SD -NRS scores, it will not be 
possible for participants t o start a sustained response less than two weeks before the Week 16 visit.  
Therefore, such participants will be censored at 14 days before the date of the Week 16 visit or at 
the time of treatment withdrawal for participants who do not complete the 16 -week treatment 
period.  
 
For the primary and secondary responder endpoints relating to EASI, IGA and BSA, summaries 
will be provided comparing the number and percentage of participants in each treatment group 
who respond at Week 16 between the following 4 subg roups:  
• Participants with no rescue therapy use  
• Participants with no rescue therapy use after the Week 4 visit  
• Participants with no rescue therapy use after the Week 8 visit  
• Participants with no rescue therapy use within 4 weeks of the Week 16 visit  
• Partici pants with no rescue therapy use within 2 weeks of the Week 16 visit  
• Participants with rescue therapy use within 4 weeks of the Week 16 visit  
• Participants with rescue therapy use within [ADDRESS_690402] Week 16 data available for the relevant endpoint 
will be included and there will be no imputation for any intercurrent events.  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 82 of 114 
For the Cohorts 1 -3 analyses, pairwise treatment differences between two EDP1815 treatment 
groups will be estimated as p art of the modelling done for the primary and secondary analyses, but 
such estimates will be considered as exploratory.  
 
For the Cohort 4 analyses of the primary and selected secondary estimands, separate models will 
be used which include the EDP1815 1.6x1 011 (Cohort 1) treatment group in addition to the Cohort 
4 EDP1815 8.0x1010 group and the Cohort 4 Matched Placebo group. From these tables, pairwise 
treatment differences between the two active EDP1815 groups will be estimated, with all such 
estimates being considered as exploratory.  
 
11.4.6.  Analysis of Safety Estimands  
All safety data will be summarized by [CONTACT_531801].  
 
11.4.7.  Other Analyses  
Tabulations will be provided for completion/withdrawal status, protocol deviations, study 
populations, dem ographic and other baseline characteristics, use of concomitant medications, and 
exposure to and compliance with IMP and emollients.  
 
11.5. Handling of Protocol Deviations  
Protocol deviations will be logged within the clinical trial management system and categor ized 
dependent on the type of deviation and its significance.  
 
Protocol deviations relating to the use of prohibited medications, to non -compliance with study 
treatment (including non -compliant emollient use) and to unblinding of the study before database  
lock will be accounted for as intercurrent events in the primary analysis.  
 
11.6. Handling of Dropouts or Missing Data  
Unless otherwise specified, missing data will be considered as missing at random and will be 
accounted for using mixed models for repeated mea sures, with all time points collected for the 
relevant endpoint included in the model.  
 
Otherwise, missing data will not be imputed.  
 
11.7. Planned Interim Analysis and Data Monitoring  
An interim analysis may be undertaken prior to the end of recruitment  for Coh orts 1,2 and 3 . The 
purpose of this interim analysis is to check the sample size assumptions for placebo response rates 
and drop -out rates .  
 
The balance of participants enrolled to each treatment group  will also be checked during this 
analysis . Due to the  use of stratification by [CONTACT_531802] -within -
cohort level, there may be up to 9 incomplete blocks of treatment assignments remaining at the 
end of randomization.  This may lead to imbalance between the cohorts and/or tr eatment groups.  
An unblinded team within the Biostatistical Vendor  will review the overall numbers of participants 
randomized to each treatment group and as a result may specify to the IRS Vendor that the 
randomization numbers for an individual cohort and /or the randomization numbers for an 

EDP1815 -[ADDRESS_690403] been made.  
 
The primary efficacy endpoint is the achievement of EASI -50 at  Week 16.  The pooled placebo 
response rate is estimated to be approximately 25% and a doubling of this to 50% for EDP1815 
would be considered as clinically meaningful.  
 
Using a two -sided test at the 5% level of significance, 58 participants in each treatm ent group 
would give 80% power to detect a difference in one of the EDP1815 cohorts compared to the 
pooled placebo group. There would also be more than 90% power to compare the pooled EDP1815 
6.4 x1011 daily dose or all the EDP1815 group to the pooled plac ebo group.  
 
Under the assumption of a 20% drop -out of participants prior to Week [ADDRESS_690404] 73 participants to be enrolled in each treatment group.  In order to allow for the 3:1 
randomization in each cohort this has been adju sted to 75 participants per treatment group to give 
a total of 300 participants recruited.  With 75 EDP1815 participants and 25 placebo participants in 
each of the three cohorts.  
 
Cohort 4  
Using the same assumptions relating to the placebo rate, clinically  meaningful difference, 
significance level, and drop -out rate as above for Cohorts 1 -3, approximately 70 participants are 
required in each of the EDP1815 8.0x1010 and Cohort 4 Matched Placebo groups to provide 
approximately 80% power in detecting a differe nce between EDP1815 and placebo in Cohort 4.  
 
In order to allow 50% of the placebo control group to be concurrent controls and 50% to be historic 
matched controls from Cohorts 1 -3, a 2:1 randomization will be used to enroll 70 EDP1815 
8.0x1010 subjects and  35 placebo participants to Cohort 4.  
 
If sensitivity analyses indicate that pooling of the Cohort 4 placebo group with the Cohort 1 -3 
matched placebo data is inappropriate, then the power of the comparison between the Cohort 4 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 84 of 114 
EDP1815 and placebo groups i s approximately 65% if only Cohort 4 placebo participants could 
be used in the treatment comparisons.    

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 85 of 114 
 
12. ETHICS AND REGULATORY REQUIREMENTS  
 
12.1. Informed Consent  
Participant’s informed consent must be obtained and documented in accordance with local 
regulatio ns, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.  
 
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the participant in both oral and written form by [CONTACT_737] (or 
designee).  Each participant will have the opportunity to discuss the study and its alternatives with 
the Investigator.  
 
Prior to participation in the study, the Informed Consent Form (ICF) should be signed and 
personally dated by [CONTACT_2299], or his/her legal representative, and by [CONTACT_37994] (Investigator or medically licensed Sub -Investigator). 
The participant or  his/her legal representative must receive a copy of the signed and dated ICF. As 
part of the consent process, each participant must consent to direct access to his/her medical 
records for study -related monitoring, auditing, IRB/IEC review, and regulatory inspection.  
 
If the ICF is amended during the study, the Investigator (or the Sponsor, if applicable) must follow 
all applicable regulatory requirements pertaining to the approval of the amended Informed Consent 
form by [CONTACT_1201]/IEC and use of the amended f orm. 
 
All studies conducted at centers in the [LOCATION_002] must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.  
 
The participant may withdraw his/her consent to participate in the study at any time. A participa nt 
is considered as enrolled in the study when he/she has signed the ICF. Study specific procedures 
may not be performed for a given participant, without having obtained his/her written consent to 
participate in the study.  
 
12.2. Participant Identification Cards  
Upon signing the Informed Consent and Assent Form(s) (as applicable), the participant or legal 
representative will be provided with a participant identification card in the language of the 
participant. The Investigator will fill in the participant identif ying information and medical 
emergency contact [CONTACT_3031]. The Investigator will instruct the participant to keep the card with 
him/her at all times.  
 
12.3. Institutional Review Boards and Independent Ethics Committees  
The study will be conducted under the ausp ices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.  
 
The Investigator and Sponsor  or their designee will ensure that an appropriately constituted  
IRB/IEC that complies with the requirements of the current ICH -GCP version or applicable 

EDP1815 -[ADDRESS_690405] copi[INVESTIGATOR_18280], Informed Consent form, Investigator’s Brochure, 
Investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other 
participant --related documents to b e used for the study to the IRB/IEC for its review and approval.  
 
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.  
 
The Investigator will also promptly report to the IRB/IE C all changes in the study, all unanticipated 
problems involving risks to human participants or others, and any protocol deviations, to eliminate 
immediate hazards to participants.  
 
The Investigator will not make any changes in the study or study conduct w ithout IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the participants. For 
minor changes to a previously approved protocol during the period covered by [CONTACT_18424], it may be possible for the Investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
allowed.  
 
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirement s), at intervals appropriate to the degree of participant risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study 
completion.  
 
The Sponsor (or its representative) will communicate safety information to the appropriate 
regulatory authorities and all active investigators in accordance with applicable regulatory 
requirements. The appropriate IRB/IEC will also be informed by [CONTACT_29539], 
as specified by t he applicable regulatory requirements in each concerned country. Where 
applicable, investigators are to provide the sponsor (or its representative) with evidence of such 
IRB/IEC notification.  
 
12.4. Participant Privacy  
The Sponsor or their designee will protect the participant’s confidentiality. Throughout this study, 
all data forwarded to the Sponsor or their designee, will be identified only by [CONTACT_531803]/or Day 1 Visit.  All personal data collected related to 
participants, Investigators, or any person involved in the study, which may be included in the 
Sponsor’s databases, shall be treated in accordance with applicable data protection law.  
 
The Investigator agrees that representatives of the Sponsor, its designee,  representatives of the 
relevant IRB/IEC, or representatives of regulatory authorities will be allowed to review that 
portion of the participant’s primary medical records that directly concerns this study (including, 
but not limited to, laboratory test res ult reports, ECG reports, admission/discharge summaries for 
hospi[INVESTIGATOR_1684] a participant’s study participation, and autopsy reports for 
deaths occurring during the study).  
 

EDP1815 -[ADDRESS_690406] 
be approved by [CONTACT_1034], the IRB/IEC, and the regulatory authorities (if required), prior to 
being implemented.  
 
12.6. Insurance  
Insurance coverage will be handled according to local requirements.  
 
12.7. Financial Disclosures  
Investigators and Sub -Investigators will p rovide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible f or providing information on financial interests during the study and for [ADDRESS_690407] fecal and oral microbiota composition in hum an 
type 1 diabetes, an observational study. PLoS One. 2017;12(12):e0188475.  
 
Atkinson. (2004). Retrieved from https://www.iqvia.com/ -/media/iqvia/pdfs/landing -
pages/treatment -satisfaction/atkinson -2004 -tsqm -14-
development.pdf?la=en&hash=D445 1E03980A36AEEF0895D6B6985DA3&_=1615920
176681  
 
Austin, P. (2011). An introductions to propensity score methods for reducing the effects of 
confounding in observational studies. Multivariate Behavioral Research, 46 (3), 399 -424. 
 
Basra. (2015). Retrieved fro m https://pubmed.ncbi.nlm.nih.gov/25613671/  
 
Bieber. (2010). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883413/  
 
Bieber. (2010). Atopic Dermatitis. Ann Dermatol. , 22(2):125 -137. 
 
Dermatitis, S. s. (1993). Severity Scoring of Atopic Derma titis: The SCORAD Index. 
Dermatology, 186 , 23-31. 
 
Dias-Barbosa, C., Matos, R., & Vernon, M. (2020). Content validity of a sleep numerical rating 
scale and a sleep diary in adults and adolescents with moderate -to-severe atopic 
dermatitis. J Patient Rep Out comes , 4, 100.  
 
EASI. (2017 Jan). Eczema Area and Severity Index (EASI) Guidance. Version 3.0.  
 
Eczema, H. f. (n.d.). Retrieved from http://www.homeforeczema.org/research/easi -for-clinical -
signs.aspx  
 
EMEA. (2002 Jul). CPMP/ICH/135/95 Note for guidance on  Good Clinical Practice [Section 
4.9.5].  
 
Finlay AY, K. G. (1994). Dermatology Life Quality Index (DLQI): a simple practical measure 
for routine clinical use. . Clin Exp Dermatol. , 19 , 210 -216. 
 
Hobbs, B., Carlin, B., Mandrekar, S., & Sargent, D. (2011). Hierarchical commensurate and 
power prior models for adaptive incorporation of historical information in clinical trials. 
Biometrics, 67 (3), 1047 -1056.  
 
Indra. (2013). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038411/  
 
Katoh. (2019). Retrieved from https://onlinelibrary.wiley.co m/doi/full/10.1111/1346 -8138.[ZIP_CODE]  
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 89 of 114 
Kiebert. (2002). Retrieved from https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365 -
4362.2002.[ZIP_CODE].x?sid=nlm%3Apubmed  
 
Lee. (2016). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773205/  
 
Leshem, Y. A. , Bissonnette, R., Paul, C., Silverberg, J. I., Irvine, A. D., Paller, A. S., . . . 
Guttman -Yassky, E. (2019). Optimization of placebo use in clinical trials with systemic 
treatments for atopic dermatitis: an International Eczema Council survey -based position 
statement. Journal of the European Academy of Dermatology and Venereology , 33(5) , 
807-815. Retrieved from Reference: Optimization of placebo use in clinical trials with 
systemic  
 
Mangalam, A., Shahi, S., & Luckey, D. (017). Human gut -derived commensal bacteria suppress 
CNS inflammatory and demyelinating disease. Cell Rep , 20(6):1269 -77. 
 
Marietta, E., Murray, J., & Luckey, D. (2016). Marietta EV, Murray JA, Luckey DH, et al. 
Human gut -derived Prevotella histicola suppresses inflammatory arthritis in humanized 
mice. Arthritis Rheumatol. 68(12):2878 -88. 
 
National Eczema Association. (201 6). https://nationaleczema.org/in -your-words -survey -series.  
 
Pariser. (2020, January 13). Evaluating patient -perceived control of atopic dermatits; design, 
validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res 
Opin. , 367 -376. 
 
Phan. (2011). Ref: Assessment of Pruritus Intensity: Prospective Study on Validity and 
Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating 
Scale in 471 Patients with Chronic Pruritus.   
 
Renert -Yuval. (2021). Retrieved from 
https://www.sciencedirect.com/science/article/pii/S0091674921000968  
 
Schatz. (2006). Retrieved from https://www.jacionline.org/article/S0091 -6749(06)[ZIP_CODE] -
6/fulltext  
 
Schram, M., Spuls, P., Leeflang, M., Lindeboom, R., Bos, J., & Schmitt, J. (2011). EASI, 
(objective) SCORAD and POEM for atopic eczema: Responsiveness and minimal 
clinically important difference. Allergy , 67(1);99 -106. 
 
Simpson. (2012). Retrieved from http s://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671606/  
 
Simpson E, B. R. (2020 Sep). The Validated Investigator Global Assessment for Atopic 
Dermatitis (vIGA -AD): The development and reliability testing of a novel clinical 
outcome measurement instrument for the  severity of atopic dermatitis. J Am Acad 
Dermatiol., 83 (3), 839 -846. 
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 90 of 114 
Snaith. (2003). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC183845/  
 
Suh. (2020). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457338/  
 
Vandeputte, D., Kathagen, G., & D'hoe, K. (2017). Quantitative microbiome profiling links gut 
community variation to microbial load. Nature , 551:507 -11. 
 
Viele, e. a. (2014). Use of historical control data for assessing treatment effects in clinical trials. 
Pharmaceutical  Statistics , 41-54. 
 
Ware J, K. M. (1996). A 12 -Item Short -Form Health Survey: construction of scales and 
preliminary tests of reliability and validity. Med Care. 1996. 34; 3:220 -33. Med. Care , 
220-233. 
 
Yosipovitch, G., Reaney, M., Mastey, V., Eckert, L.,  Abbe, A., Nelson, L., . . . Gadkari, A. 
(2019). Peak Pruritus Numerical Rating Scale: psychometric validation and responder 
definition for assessing itch in moderate -to-severe atopic dermatitis. The British Journal 
of Dermatology , 181(4), 761 -769. 
 
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 91 of 114 
14. APPENDICES  
14.1. Hanifin and Rajka (1980) Criteria for Diagnosis of Atopic Dermatitis  
 
From Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;92 
(Suppl):44 -47. 
 
Major Features : must have 3 or more of the following:  
1. Pruritus  
2. Typi[INVESTIGATOR_22784]:  
a. Flexural lichenification or linearity in adults  
b. Facial and extensor involvement in infants and children  
3. Chronic or chronically -relapsing dermatitis  
4. Personal or family history of atopy (asthma, allerg ic rhinitis, atopic dermatitis)  
 
Minor Features: plus 3 or more of the following:  
1. Xerosis  
2. Ichthyosis / palmar hyperlinearity /keratosis pi[INVESTIGATOR_22785]  
3. Immediate (type 1) skin -test reactivity  
4. Raised serum IgE  
5. Early age of onset  
6. Tendency toward cutaneous infections  (especially Staph. aureus and Herpes simplex) or 
impaired cell -mediated immunity  
7. Tendency toward non -specific hand or foot dermatitis  
8. Nipple eczema  
9. Cheilitis  
10. Recurrent conjunctivitis  
11. Dennie -Morgan infraorbital fold  
12. Keratoconus  
13. Anterior subcapsular catarac ts 
14. Orbital darkening  
15. Facial pallor / facial erythema  
16. Pi[INVESTIGATOR_80166]  
17. Anterior neck folds  
18. Itch when sweating  
19. Intolerance to wool and lipid solvents  
20. Perifollicular accentuation  
21. Food intolerance  
22. Course influenced by [CONTACT_222224] / emotional factors  
23. White dermographism / delayed blanch  
 
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 92 of 114 
14.2. Classification of Potency of Topi[INVESTIGATOR_531767]1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 93 of 114 
14.3. Contraceptive Guidance and Collection of Pregnancy Information  
Definitions  
Woman of Child -Bearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
 
Women in the following categories are not considered WOCBP:  
1. Premenarchal  
 
2. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
• Documented bilateral tubal ligation  
 
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
 
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for [ADDRESS_690408] pregnancy tests performed 
throughout the course of the study per the Schedule of Activities (SOA).  
 
• Females on HRT and whose menopausal status is in doubt will be required to use 
one of the non -oestrogen hormona l highly effective contraception methods if they 
wish to continue their HRT during the study.  
 
Contraception Guidance  
 
Male participants with a female partner of child -bearing potential must either  
• Be abstinent from penile -vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent  
 
• Use a male condom during each epi[INVESTIGATOR_322410] [ADDRESS_690409] dose of IM P.  
 
• Have a confirmed vasectomy.  
 
In addition, all male participants must refrain from donating sperm for the duration of the study 
and for at least [ADDRESS_690410] dose.  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 94 of 114 
Female participants  
Female participants of child -bearing potential are eligible to participate if they agree to use a highly 
effective method of contraception consistently and correctly as described in Table 14-1 below . 
 
Table 14-1: Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependent a  
Failure rate of < 1% per year when used consistently and correctly.   
 Combined (oestrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulationb. 
• Oral  
• Intravaginal  
• Transdermal  
 Progestogen only hormonal contraception associated with inhibition of ovulation  
• Oral  
• Injectable  
Highly Effective Methods That Are User Independent a  
• Implantable progestogen only hormonal contraception associated with inhibition of 
ovulationb. 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilatera l tubal occlusion  
 Vasectomised partner  
A vasectomised partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be u sed.  
 Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention, 
including at least 1 complete menstrual cycle (cycle (≥ 30 days) for women and [ADDRESS_690411] dose. The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the study and the preferred and usual lifestyle of the participant.  
NOTES:  
a) Typi[INVESTIGATOR_531768]. Use 
should be consistent with local regulations regarding the use of contraceptive methods for 
participants participating in clinical studies.  
b) Hormonal contraception may be susceptible to interaction with the study intervention, 
which may reduce the efficacy of the contraceptive method. In this case, a highly effective 
method of contraception plus condoms should be utilised during their partic ipation in the 
study up to and including at least 1 complete menstrual cycle (≥ 30 days) for women and 
[ADDRESS_690412] dose.  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 95 of 114 
Pregnancy Testing  
• WOCBP should only be included after a confirmed menstrual period and a negative 
pregnancy test.  
• Pregnancy testing is required at screening.  
• Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.  
 
Collection of Pregnancy Information  
Male participants with partners who become pregnant  
• The In vestigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies to all male participants who receive EDP1815.  
 
• After obtaining the necessary si gned informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 24  hours of learning of the partner’s pregnancy. The female 
partner will also be  followed to determine the outcome of the pregnancy. Information on 
the status of the mother and child will be forwarded to the Sponsor. Generally, the follow -
up will be no longer than 8  weeks following the estimated delivery date. Any termination 
of the p regnancy will be reported regardless of foetal status (presence or absence of 
anomalies) or indication for the procedure.  
Female participants who become pregnant  
• The investigator will collect pregnancy information on any female participant who 
becomes pr egnant while participating in this study. Information will be recorded on the 
appropriate form and submitted to the Sponsor within 24  hours of learning of a participant's 
pregnancy. The participant will be followed to determine the outcome of the pregnancy . 
The investigator will collect follow -up information on the participant and the neonate and 
the information will be forwarded to the Sponsor. Generally, follow -up will not be required 
for longer than 6  to 8 weeks beyond the estimated delivery date. Any te rmination of 
pregnancy will be reported, regardless of foetal status (presence or absence of anomalies) 
or indication for the procedure.  
 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a p regnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post -study 
pregnancy related - SAE considered reasonably related to the study intervention by [CONTACT_531804] 9.5 Reporting Serious 
Adverse Events . While the Investigator is not obligated to actively seek this inf ormation 
in former study participants, he or she may learn of an SAE through spontaneous reporting.  
 
• Any female participant who becomes pregnant while participating in the study will 
discontinue study intervention or be withdrawn from the study.  

EDP1815 -[ADDRESS_690413] the virus, which involves the synthesis of 
Type 1 interferons and the stimulation of Natural Killer (NK) cells. If the infection proceeds 
beyond the first few rounds of viral replication, the innate immune response will trigger the 
adaptive immune response. The adaptive immune response itself has two components, the humoral 
response (the synthesis of virus -specific antibodies by B lymphocytes) and the cell -mediated 
response (the synthesis of specific CD8+ cytotoxic T lymphocytes that  kill infected cells). Both of 
these components of the adaptive immune response result also in the production of long -lived 
memory cells that allow for a much more rapid response to a subsequent infection with the same 
virus.  Thus, an immune competent hos t should be able to mount both an innate and adaptive 
immune response.   
EDP1815 is a single strain of human commensal Prevotella histicola  that is being clinically tested 
to treat inflammatory skin diseases such as psoriasis and atopic dermatitis (studies  1815 -101, 1815 -
201, and 1815 -207); in a pharmacodynamic immune challenge study to Keyhole Limpet 
Haemocyanin (KLH) (study 1815 -102); and also to treat the complications of infection with 
COVID -19 (study 1815 -204 and 1815 -205).  EDP1815 is administered ora lly and is gut -restricted.  
Therefore, EDP1815 exerts its anti -inflammatory effects on peripheral tissue through engagement 
of cells of the intestine, including small intestinal epi[INVESTIGATOR_531769].   
EDP1815 has been sh own in preclinical mouse inflammation models to reduce antigen -specific T 
cell responses, without impacting:  
• The anti -viral TLR3 -mediated Type 1 interferon (alpha and beta) response  
• Interferon -gamma production by T cells and NK cells  
• Immune cell subsets ( absolute number and percentage), including CD8 T lymphocytes, B 
lymphocytes, and myeloid lineage cells  
• The antigen -specific antibody responses (IgM and IgG)  
In human immune cell in vitro assays, EDP1815 did not alter the ability of human dendritic cells 
to induce the production of interferon -gamma from memory CD8 T cells in response to a viral 
peptide pool ( Cytomegalovirus, Epstein -Bar virus, and Influenza virus) , an important component 
of an anti -viral response.  
And clinically, treatment with EDP1815 was s hown to reduce specific inflammatory myeloid cell 
cytokines such as IL -[ADDRESS_690414] on KLH -specific IgM or IgG has been observed in either preclinical models or in 
a clinical study (data not shown).  
 
In vitro assay co -culture with human dendri tic cells and CD8 T cells  
 
An in vitro assay with primary human DCs and autologous CD8+ T cells was carried out to 
measure the capacity of EDP1815 to modulate antigen -specific CD8+ T cell responses. Briefly, 
primary human DCs from 3 healthy donors were di fferentiated in vitro for 7 days. To assess the 
immuno -modulatory properties of EDP1815, DCs were incubated with EDP1815 or ES880, a 
different Prevotella  strain that does not exhibit anti -inflammatory activity, for 24 hours in vitro. 
After 24 hours of microbe conditioning, microbes were removed from the DC culture and 
autologous human CD8+ T cells and CEF Class I peptide pool was added. The CEF peptide poo l 
is composed of peptides from Cytomegalovirus, Epstein Bar virus, and Influenza virus, pathogens 
to which the majority of the human population has been exposed. After 24 hours of stimulation 
with CEF peptide, DC -CD8+ T cell supernatants were collected and  IFNγ was measured. When 
human DCs were incubated with EDP1815, the IFNγ response to CEF was not affected (neither 
enhanced nor decreased) compared to the DC -CD8 T cell co -culture control.  In contrast, 
incubation with ES880 led to increased production of IFNγ.  
Vehicle
EDP181505×1051×106Cell number (absolute)B cells
Vehicle
EDP181501×1042×1043×104Cell number (absolute)Neutrophils
Vehicle
EDP18150.05.0×1041.0×1051.5×1052.0×1052.5×105Cell number (absolute)Macrophages
Vehicle
EDP18150 05.0×1031.0×1041.5×104Cell number (absolute)Monocytes

EDP1815 -[ADDRESS_690415] response.  
 
 
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 101 of 114 
14.5. Toxicity Grading Scale  
The following scales come from the FDA Guidance for Industry Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials , September 2007.  
 
Temperature Adverse Event Grading Scale  
 
Vitals Signs*  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  Potentially Life 
Threatening (Grade 
4) 
Fever (ºC)**  
          (ºF)**  38.0 – 38.4 
100.4 – 101.1  38.5 – 38.9 
101.2 – 102.0  39.0 – 40 
102.1 - 104 > 40  
>[ADDRESS_690416] this clinical 
study as outlined in this protocol, according to current Good Clinical Practice (GCP) and local 
laws and requirements.  
 
I will ensure that all Sub -Investigators and other staff members read and understand all aspects of 
this protocol.  
 
I have received and read all study -related inf ormation provided to me.  
 
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by [CONTACT_429], Evelo Biosciences, Inc . 
 
All rights of publication of the results reside with the Sponsor, Evelo Biosciences, Inc, unless other 
agreements were made in a separate contract.  
 
 
  
Signature [CONTACT_531806] (City)   
 
  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 106 of 114 
as non -responders at the Week 
16 visit.  
 
2.3 Exploratory Objectives  
 
4.3 Exploratory Variables  Following exploratory objective was 
added to the protocol:  
 
• To evaluate the effect of early 
use of rescue therapy on We ek 
16 responder status.  
 
Additionally, exploratory variables 
were updated to include the 
following:  
 
• To evaluate the effect of early 
use of topi[INVESTIGATOR_531770] [ADDRESS_690417] 4, 8, 12 and 14 weeks 
prior to the Week 16 visit.  For 
these subgroups, the following 
endpoints will be summarized:  
Percentage of Pa rticipants 
Achieving EASI -50, EASI -75 
and EASI -90. 
• Percentage of Participants 
Achieving IGA 0 or 1, with and 
without a 2 -point improvement 
from Baseline  
• Percentage of Participants 
Achieving BSA -[ADDRESS_690418](s)  
 
Table 6 -1: IMP to be Administered  Added Cohort [ADDRESS_690419] been collected 
thus far for required microbiome 
analyses.  
5.1 Inclusion Criteria  
 Inclusion criterion # 4 update to 
clarify IGA caps.  The bolded, 
underlined text was added to this 
criterion:  
 
7. Have severity of atopic 
dermatitis meeting the below 
criteria at both Screening and 
Day 1:  
i. An IGA of 2, 3 or 4 on 
the vIGA scale, and;  
ii. A BSA of ≥5%, and;  
iii. An EASI score of ≥6.  
 
A cap will be set for each of the 
three IGA severity grades. When 
this cap is reached, Sponsor will 
notify sites and participants with 
severity score at Screening and/or 
Day [ADDRESS_690420] ing to Inclusion Criterion 4i. 
See Section 11.7  Planned Interim 
Analysis and Data Monitoring.  
 Changes were made to inclusion 
criterion #4 in order to allow for a 
cap  
 
5.2 Excl usion Criteria  Exclusion criterion #20 changed 
from the strikethrough text to the 
bolded, underlined  text below:  
 
20. Active untreated mental or 
psychiatric disorder. 
Participants who are on 
stable dosing of medication 
for a mental or psychiatric 
disorder for at least 6 months 
before signing of ICF and 
whose treating physicians 
consider them to be mentally 
stable may be enrolled.  
 
Change to:  
 
20. Active mental or psychiatric 
disorder, which, in the 
opi[INVESTIGATOR_531771] #20 in order to allow 
physician judgement of inclusion of 
participants with an untreated 
mental or psychiatric disorder in the 
study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 108 of 114 
Sponsor, would make the  
participant unsuitable for 
inclusion or could interfere 
with the participant 
participating in or completing 
the study.  
 
Exclusion criterion #23 updated to 
remove the strikethrough text and 
include the bolded, underlined text:  
 
23. Treatment with another 
investigational drug or 
device within 3 months of 
signing the ICF  or 5 half -
lives of investigational agent, 
prior to randomization  
whichever is longer.  
  
 
 
 
 
 
 
Changes were made to exclusion 
criterion #[ADDRESS_690421](s)  
 Description of EDP1815 enteric -
coated capsules updated to include 
Cohort 4 drug substance description 
and manufacturing details.  
 Cohort 4 added to study protocol.  
9.12.3 12 -Lead Electrocardiogram  The following, strik ethrough text 
was removed from this section:  
 
A single 12 -lead electrocardiogram 
(ECG) will be obtained at specified 
visits using an ECG machine that 
automatically calculates heart rate 
and measures PR, RR, QRS, QT and 
QTcF (Fridericia) intervals.  If the 
ECG machine does not calculate 
QTcF, this will be calculated by [CONTACT_531805].  
 Electronic Data Capture (EDC) 
calculates QTcF intervals as a 
derived field.  
10.2.1 Definition of Source Data  The following bolded, underlined  
text added to  this guidance:  
 
The following data will be 
considered as electronic source and 
therefore, will not be recorded 
directly into the EDC and will not 
appear in a separate source 
document as defined above, unless 
there is a circumstance, such as a 
global power  outage, making it 
difficult for site staff to collect this 
data electronically. Any information 
about a participant that is collected 
during this study will remain 
secured and confidential and will be 
handled per applicable regulations 
(i.e., data collect ed via mobile 
applications).  Text added to ensure that data is not 
missed and is collected at a 
minimum via paper when electronic 
means are not possible due to 
unforeseen circumstances.  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 109 of 114 
 
 
   
14.3 Contraceptive Guidance and 
Collection of Pregnancy 
Information  The following bolded, underlined  
text added to this guidance:  
 
Women in the following categories 
are not considered WOCBP:  
4. Premenarchal  
 
5. Premenopausal female 
with 1 of the following:  
• Documented 
hysterectomy  
• Documented 
bilateral 
salpi[INVESTIGATOR_1656]  
• Documented 
bilateral 
oophorectomy  
• Documented 
bilateral tubal 
ligation  
 To further clarify that women with 
documented bilateral tubal ligation 
are not considered WOCBP and 
may be considered for enrollment 
in the study without the use of 
additional contraception.  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 111 of 114 
 11.2 General Statistical 
Considerations  
 
11.3.1 Primary Estimand and 
Supplementary Estimands of the 
Primary Objective  
 
11.3.2 Secondary Estimands  
 
11.8 Determination of Sample Size  
 Language amended to clarify how 
data will be pooled and compared 
across the 3 treatment cohorts.  The change to cohort 1 meant that 
the ‘all EDP1815’ vs placebo 
comparison was no longer 
appropriate as a primary analysis. In 
addition, the exploratory 
compari sons between EDP1815 
groups required updating.  
Table 11 -1: Intercurrent Event 
Strategies for the Primary and 
Supplementary Estimands  
 
Table 11 -2: Secondary Estimand 
Details  
 
 Estimands clarified and reordered 
throughout both tables.  Minor corrections to i ssues found 
since finalization of V3  

EDP1815 -207  Clinical Study Protocol  EVELO  
Version 5.0  25 April 2022  
  Page 114 of 114 
 Protocol Summary  
 
4. Study Design  
 
4.6. Schematic Study Diagram  Change in number of participants 
per cohort: [ADDRESS_690422] lesions 
present at the start of the study.  
5.2 Exclusion Criteria  Exclusion criteria #2 updated to 
exclude all participants with prior 
exposure to EDP1815.  
 Alignment with other Evelo 
protocols  
6.9.1 Permitted Concomitant 
Medications and Treatments  
 
[IP_ADDRESS]. Rescue Therapy  Additional language added to allow 
antimicrobial therapy for secondary 
skin infections with permitted 
treatments listed.  
 
Language amended to allow rescue 
therapy throughout entire treatment 
period.  
 Addresses FDA hold item  
9.4.1 Assessments of AE s Language added to clarify how AEs 
will be solicited from the 
participant.  
 Addresses FDA hold item  
9.4.2 Assessments of Severity of 
AEs Language added to clarify that 
abnormal laboratory results that are 
found to be clinically significant 
adverse events  will be graded 
according to the FDA Guidance for 
Industry Toxicity Grading Scale.  
 Added per the FDA’s 
recommendation.  
